Investigation of the radiation dose from cone beam CT for image guided radiotherapy: a comparison of methodologies by Buckley, Jarryd
University of Wollongong 
Research Online 
University of Wollongong Thesis Collection 
2017+ University of Wollongong Thesis Collections 
2017 
Investigation of the radiation dose from cone beam CT for image guided 
radiotherapy: a comparison of methodologies 
Jarryd Buckley 
University of Wollongong 
Follow this and additional works at: https://ro.uow.edu.au/theses1 
University of Wollongong 
Copyright Warning 
You may print or download ONE copy of this document for the purpose of your own research or study. The University 
does not authorise you to copy, communicate or otherwise make available electronically to any other person any 
copyright material contained on this site. 
You are reminded of the following: This work is copyright. Apart from any use permitted under the Copyright Act 
1968, no part of this work may be reproduced by any process, nor may any other exclusive right be exercised, 
without the permission of the author. Copyright owners are entitled to take legal action against persons who infringe 
their copyright. A reproduction of material that is protected by copyright may be a copyright infringement. A court 
may impose penalties and award damages in relation to offences and infringements relating to copyright material. 
Higher penalties may apply, and higher damages may be awarded, for offences and infringements involving the 
conversion of material into digital or electronic form. 
Unless otherwise indicated, the views expressed in this thesis are those of the author and do not necessarily 
represent the views of the University of Wollongong. 
Recommended Citation 
Buckley, Jarryd, Investigation of the radiation dose from cone beam CT for image guided radiotherapy: a 
comparison of methodologies, Master of Science - Research thesis, School of Physics, University of 
Wollongong, 2017. https://ro.uow.edu.au/theses1/100 
Research Online is the open access institutional repository for the University of Wollongong. For further information 
contact the UOW Library: research-pubs@uow.edu.au 
INVESTIGATION OF THE RADIATION DOSE
FROM CONE BEAM CT FOR IMAGE GUIDED
RADIOTHERAPY: A COMPARISON OF
METHODOLOGIES
A Thesis Submitted in Partial Fulfilment of
the Requirements for the Award of the Degree of





Bachelor of Medical and Radiation Physics
School of Physics







List of Tables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . iv
List of Figures/Illustrations . . . . . . . . . . . . . . . . . . . . . . . . . . . ix
ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . x
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xiii
1 Introduction 1
1.0.1 Research Aims . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
2 Literature Review 4
2.1 Radiotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
2.1.1 External Beam Therapy . . . . . . . . . . . . . . . . . . . . . . 5
2.1.2 Interactions of kV Ionising Radiation . . . . . . . . . . . . . . . 6
2.1.3 Dosimeters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
2.2 Image Guided Radiation Therapy . . . . . . . . . . . . . . . . . . . . . 12
2.2.1 Image Guidance Modalities . . . . . . . . . . . . . . . . . . . . 13
2.2.2 kV Imaging System . . . . . . . . . . . . . . . . . . . . . . . . . 15
2.3 Radiation Dose from kV CBCT Image Guided Radiotherapy . . . . . . 21
2.3.1 Computed Tomography Dose Index . . . . . . . . . . . . . . . . 23
2.3.2 Limitations of CTDI . . . . . . . . . . . . . . . . . . . . . . . . 28
2.3.3 Alternative Protocols for Wide-Beam Dosimetry . . . . . . . . . 29
2.4 Low Dose Radiation and Secondary Cancer Risk . . . . . . . . . . . . . 35
2.4.1 Studies of Atomic Bomb Survivors . . . . . . . . . . . . . . . . 35
2.4.2 Secondary Cancer Risk from Radiotherapy Procedures . . . . . 37
2.4.3 Risk Models for Low Dose Radiation . . . . . . . . . . . . . . . 38
3 Evaluating CTDI, CBDI, IAEA and TG111 Methodologies for Clin-
ical CBCT Settings 43
3.1 Measuring the CTDI and CBDI . . . . . . . . . . . . . . . . . . . . . . 43
3.1.1 Phantom Design and Materials . . . . . . . . . . . . . . . . . . 43
3.1.2 OBI and XI systems . . . . . . . . . . . . . . . . . . . . . . . . 45
3.1.3 Determination of CTDI and CBDI . . . . . . . . . . . . . . . . 47
3.2 IAEA Report 5 Protocol . . . . . . . . . . . . . . . . . . . . . . . . . . 54
3.2.1 IAEA Measurements . . . . . . . . . . . . . . . . . . . . . . . . 56
3.3 AAPM TG111 Methodology . . . . . . . . . . . . . . . . . . . . . . . . 58
i
TABLE OF CONTENTS ii
3.3.1 Phantom Design and Materials . . . . . . . . . . . . . . . . . . 58
3.3.2 Determining air KERMA Conversion Values . . . . . . . . . . . 64
3.3.3 TG111 Measurements . . . . . . . . . . . . . . . . . . . . . . . 65
3.4 Comparison of Methodologies . . . . . . . . . . . . . . . . . . . . . . . 66
4 Beam Profile Measurements and the Dosimetric Impact of Increased
Beam Width 70
4.1 Variation of Central Dose with Increasing Scan Length . . . . . . . . . 70
4.1.1 Beam Width Measurements . . . . . . . . . . . . . . . . . . . . 71
4.2 Integral Dose . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
4.2.1 Integral Dose Measurements . . . . . . . . . . . . . . . . . . . . 74
4.2.2 Integral Dose for Increasing Beam Width . . . . . . . . . . . . . 75
4.3 CBCT Beam Profiles . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
4.3.1 Ionisation Chamber Measurements . . . . . . . . . . . . . . . . 77
4.3.2 Film Measurements . . . . . . . . . . . . . . . . . . . . . . . . . 79
4.4 Calculating the CTDI using Film Strips . . . . . . . . . . . . . . . . . 93
5 Conclusion 98
5.1 Comparison of TG111, CBDI and IAEA methodologies with the current
CTDI method . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
5.2 Comparison of dose with varying beam width for TG111, CBDI, IAEA
and CTDI, including Integral Dose . . . . . . . . . . . . . . . . . . . . 100
5.3 Comparing the dose of the OBI and XI kV CBCT imaging systems . . 101
5.4 Summary and Future Work . . . . . . . . . . . . . . . . . . . . . . . . 101
References 120
List of Tables
2.1 Summary of doses in cGy from imaging modalities used in radiotherapy 15
2.2 Effective dose per scan kV CBCT for head and neck, thorax and pelvis
protocols. (std dose) and (low dose) refer to different scan settings, with
low dose using a lower mAs. The order of magnitude variation between
studies is likely due to older scan algorithms having much higher expo-
sures compared with newer versions. Studies which did not provide an
uncertainty for their values are indicated by *. . . . . . . . . . . . . . . 22
2.3 Summary of publications evaluating dose from kV CBCT imaging. . . . 24
2.4 CBDIw studies for head, thorax and pelvis scans in mGy normalised
per 100mAs. Normalised values provide a means of comparison between
different imaging systems with varying mAs. . . . . . . . . . . . . . . . 30
2.5 ICRP 103 Tissue Weighting Factors . . . . . . . . . . . . . . . . . . . . 41
3.1 Modes and parameters for the OBI CBCT imaging system. . . . . . . . 46
3.2 Modes and parameters for the Truebeam XI CBCT imaging system. . . 46
3.3 Scan parameters for CTDI calculations on SOMATOM CT . . . . . . . 49
3.4 Calculated CTDIw and
nCTDIw in mGy for clinical protocols on a SO-
MATOM CT scanner. The normalized values are per 100mAs. Quoted
uncertainties represent 1 standard deviation. . . . . . . . . . . . . . . 49
3.5 Scan parameters for CBCT protocols on the OBI system . . . . . . . . 51
3.6 Scan parameters for CBCT protocols on the XI system. The mAs for
the Pelvis Obese scan couldn’t be determined as the parameters were
not available from the Truebeamr imaging manual. . . . . . . . . . . . 51
3.7 Calculated CTDIw and
nCTDIw values in mGy for clinical CBCT pro-
tocols on the OBI and XI systems. Uncertainties represent 1 standard
deviation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
3.8 Calculated CBDIw and
nCBDIw values in mGy for clinical CBCT
protocols on the OBI and XI systems. . . . . . . . . . . . . . . . . . . . 53
3.9 Calculated CTDIrefin−air and CTDI
protocol
in−air values in mGy for clinical
CBCT protocols and the ratio of the two for the OBI and XI systems. . 57
3.10 Calculated IAEAw and
nIAEAw values in mGy and mGy.100mAs
−1
for clinical CBCT protocols on the OBI and XI systems. Uncertainties
represent 1 standard deviation. . . . . . . . . . . . . . . . . . . . . . . 57
iii
LIST OF TABLES iv
3.11 Calibration HVL values for settings tested on the Ortho-Voltage unit.
The calibrated values were determined from machine QA following the
TG61 protocol. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
3.12 HVL and corresponding air KERMA corrections for the farmer cham-
ber. The corrections were determined from the curve fit of the ARPANSA
data 3.12. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
3.13 Calculated TG111w and
nTG111w values in mGy and mGy.100mAs
−1
for clinical CBCT protocols on the OBI and XI systems. Uncertainties
represent 1 standard deviation. . . . . . . . . . . . . . . . . . . . . . . 66
3.14 Calculated CTDI, CBDI, IAEAw and TG111w values in mGy for
clinical CBCT protocols on the OBI system. Uncertainties represent 1
standard deviation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
4.1 Comparison of weighted measurements for CTDI, CBDI, IAEA and
TG111 protocols in mGy for the OBI Pelvis scan mode. A CTDI phan-
tom was used for CTDI, CBDI and IAEA measurements, while the
TG111 phantom was used for TG111 measurements. . . . . . . . . . . 71
4.2 Deq (mGy) and Etot (mJ) for the Pelvis and Thorax modes on the OBI
and XI imaging systems. A 1 percent error was applied to for Deq
measurements. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
4.3 Etot in mJ for increasing beam width for OBI Pelvis, OBI Thorax, XI
Pelvis, XI Pelvis Obese and XI Thorax. . . . . . . . . . . . . . . . . . . 75
4.4 Comparison of TG111w with CTDI
w
film in mGy for the OBI and XI
imaging systems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96
List of Figures
2.1 Truebeamr LINAC is capable of delivering MV X-Ray and electron
therapy as well as IGRT via its X-Ray imaging unit. Varian Medical
Systems c© . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
2.2 Schematic diagram of dominant photon interactions vs incident photon
energy. For energy ranges typical of imaging and radiotherapy (above
80-100 keV), the Compton and photoelectric effects are the dominant
interactions, and the only interactions for imaging energies as pair pro-
duction doesn’t occur in the kilovoltage energy range. Also visible is
the increased contribution of photo-electric absorption with increasing
atomic number of absorber. Source: Encyclopaedia of Occupational
Health and Safety. Fourth Edition . . . . . . . . . . . . . . . . . . . . . 6
2.3 Quantum detection efficiency (QDE) for kV and MV energies for flat-
panel imagers. The QDE is higher for kV energies than for MV . . . . 8
2.4 Filtered spectrum of Bremmstrahlung and characteristic radiation from
a tungsten target for a 90 kV potential. . . . . . . . . . . . . . . . . . . 9
2.5 Varian Clinic IXr with OBI imaging system. The X-ray tube and flat-
panel detector are mounted to the gantry 180 degrees to one another on
retractable arms which are extended for kV imaging as shown. Cour-
tesy: www.Varian.com . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
2.6 GS-1542 X-ray tube schematic from the XI imaging system. . . . . . . 17
2.7 kV collimation and filtration on the XI imaging system. . . . . . . . . . 18
2.8 (a)Bow-tie filters used for CBCT filtration. The size of the FOV dictates
the filter with small FOV head scans using the full-fan(A) while larger
FOV scans use the half-fan(B). (b)Diagrammatic representation of full-
fan vs half-fan scanning. Full-fan scanning (a-partial scan)(b-full scan)
is used for scanning smaller targets. The collimation is symmetric and
the beam is centred on isocentre. Half-fan scanning (c)(d) acquires a
larger FOV using an asymmetric beam offset from centre. . . . . . . . . 19
2.9 Schematic overview of the flat panel TFT array detector. Each detector
element consists of a TFT, a charge collection electrode and a storage
capacitor. Courtesy: www.arosystems.com.au . . . . . . . . . . . . . . . 20
v
LIST OF FIGURES vi
2.10 Large area active matrix array for X-ray TFT detector with (a) direct
conversion using a photo conductor layer with pixel electrodes and (b)
indirect conversion using a phosphor layer and photo diodes. . . . . . . 20
2.11 Diagram of axis for imaging. The axial plane is defined as the plane in
the x-y axis. Linac schematic courtesy of http://www.suggest-keywords.com 25
2.12 Head and Body CTDI phantoms for CTDI measurements. The Body
phantom is 32 cm diameter and the head phantom 16 cm in diameter.
Both phantoms are 15 cm in length. . . . . . . . . . . . . . . . . . . . . 26
2.13 CTDI100 measurement efficiency for a 32 cm PMMA phantom as a
function of scanning length for a 120kVp beam. . . . . . . . . . . . . . 31
2.14 Efficiency of the IAEA method compared with CTDI∞ for head(a-b)
and body(c-d) phantoms for 200 and 360 degree rotations. . . . . . . . 33
2.15 Approach to equilibrium at the central and peripheral locations within
a body PMMA phantom measured with a farmer chamber. Also shown
are the approach to equilibrium functions with their respective coefficients. 34
2.16 Schematic diagram of different possible radiation risks extrapolated
from measured radiation risk to low doses. Curve a-linear extrapo-
lation, curve b-downwardly curving, curve c-upwardly curving, curve
d-threshold and curve e-hormetic. Data points indicate the lower limit
of doses where significant risks have been demonstrated in human pop-
ulations (10-50 mSv for acute exposure). . . . . . . . . . . . . . . . . . 39
3.1 PMMA 32cm CTDI body phantom with the pencil chamber in the
central position. For head protocols the 16cm inner phantom was used. 44
3.2 The RaySafe Xi system used for CTDI and CBDI measurements. The
CT pencil chamber detector has a sensitive length of 100mm. The HVL
tool measures beam quality for kV energies. Both connect to the base
unit which gives a readout with temperature and pressure corrections
applied. Source: www.raysafe.com . . . . . . . . . . . . . . . . . . . . 45
3.3 Measured CTDIw and CTDIvol values taken from the scanner for Prostate
Seeds with 5mm and 10mm slice width, Head and Neck and Extreme
Clinical Limits modes. The measurements for the Head and Neck pro-
tocol were taken in the 32cm diameter CTDI phantom. The error bars
represent 2 standard deviations or 95% CI. . . . . . . . . . . . . . . . . 50
3.4 Diagram demonstrating the measurement of CTDI free in-air stepping
the 100 mm chamber in increments equal to the chamber length. . . . . 55
3.5 100 mm chamber extended from couch by support structure for free
in-air measurements. The distance of the chamber from the couch is
greater than half the beam width . . . . . . . . . . . . . . . . . . . . . 56
3.6 TG111 phantom constructed in-house at the University of Wollongong.
(a) The length was made to be 45cm to reach scatter equilibrium in the
central position. (b) The cylindrical shape and diameter of 32cm is the
same as the CTDI phantom. There are 5 plugs within the phantom for
CTDIw measurements. . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
LIST OF FIGURES vii
3.7 (a) Each slice was individually cut and milled to house plus for ionisation
chamber measurements. (b) One of the 4 PMMA plugs that fill the
unused chamber holes. (c) Single phantom slice side on. The width of
each slice was 4.7 cm. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
3.8 Plug housing 0.6cc farmer ionisation chamber in the TG111 phantom.
The plug contains 3 sections, one to run the cable out of the phantom,
a middle section milled to conform to the chamber and a solid front
section to fill the plug housing. . . . . . . . . . . . . . . . . . . . . . . 60
3.9 (a) Determination of the HVL on the orthovoltage unit using the UN-
FORS HVL tool. A 5cm diameter cone is attached at 30cm SSD. (b)
Back scatter correction measurements were taken with the 10 cm diam-
eter cone on a low-scatter stand. . . . . . . . . . . . . . . . . . . . . . . 62
3.10 kV tube output as a function of time for the ortho-voltage measurement.
By introducing a 2s trigger delay a uniform kV was obtained for the
HVL measurement. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
3.11 Set-up for the measurement of HVL on the CBCT imaging systems. The
UNFORS HVL tool was placed on the treatment couch at isocentre and
scanned under CBCT clinical mode parameters in kV fluoroscopy mode.
The detector was oriented orthogonally to the cathode-anode direction. 64
3.12 Curve fit of air KERMA per PC from ARPANSA calibration report. . . 65
3.13 A comparison of CTDI, CBDI, IAEA and TG111 weighted values on
the four full-fan CBCT modes studied. Error bars represent 1 standard
deviation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
4.1 Weighted dose measurements with increasing z-axis beam width for
CTDI, CBDI, IAEA and TG111 protocols. The OBI Pelvis scan mode
was used for all measurements. . . . . . . . . . . . . . . . . . . . . . . 72
4.2 Integral Dose with increasing beam width for Pelvis modes. . . . . . . . 76
4.3 Integral Dose with increasing beam width for Thorax modes. . . . . . . 76
4.4 Farmer chamber measurements converted to mGy of the beam profiles
along the z-axis for OBI and XI Pelvis modes in the centre of the TG111
phantom. The average collimated field width is shown with blue vertical
lines (206mm for OBI and 214mm for XI). The asymmetry in the XI
profile is due to the heel effect. . . . . . . . . . . . . . . . . . . . . . . . 78
4.5 Comparison of mean pixel intensity across the selected ROI on the cal-
ibration film pieces along the z-axis for measured doses on the OBI
system. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
4.6 Comparison of mean pixel intensity across the selected ROI on the cal-
ibration film pieces along the z-axis for measured doses on the XI system. 81
LIST OF FIGURES viii
4.7 (a) In-air calibration of XR-QA2 film. Three pieces of film were used
for each exposure. The pieces were placed along the z-axis, with one at
isocentre and one directly above and below. (b) Calibration of Farmer
chamber at isocentre with R/F detector fixed to couch away from isocen-
tre. By calibrating the isocentre dose with the R/F detector, dose to
film during exposures was able to be determined. . . . . . . . . . . . . 83
4.8 (a) In phantom calibration of XR-QA2 film. Three pieces of film were
taped in place within a PMMA plug that was sliced along its length.
The orientation of the film pieces relative to isocentre was the same as
for the in-air method. (b) Calibration of Farmer chamber at isocentre
with R/F detector held in the beam away from isocentre. . . . . . . . . 84
4.9 Comparison of the calibration data for in-air and in-phantom methods
for the OBI system. No difference in film response was observed between
the two methods. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
4.10 Comparison of the calibration data for in-air and in-phantom methods
for the XI system. The response of the film was greater when calibrating
in phantom compared with calibration in air. . . . . . . . . . . . . . . . 85
4.11 Calibration curve for the OBI imaging system. Error bars represent the
standard deviation in the net reflectance σnet∆R . . . . . . . . . . . . . 86
4.12 Calibration curve for the XI imaging system. Error bars represent the
standard deviation in the net reflectance σnet∆R . . . . . . . . . . . . . 86
4.13 Film strips for beam profile measurements. The strips were cut to 3 cm
by 30 cm and placed in the centre of the TG111 phantom in a custom
plug to reduce air gaps. . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
4.14 Dose profile (in cGy) along the z-axis for the OBI Pelvis scan in the
centre of the TG111 phantom measured using the Farmer chamber and
3cm by 30cm film strip. . . . . . . . . . . . . . . . . . . . . . . . . . . 88
4.15 Dose profile (in cGy) along the z-axis for the XI Pelvis scan in the centre
of the TG111 phantom measured using the Farmer chamber and 3cm
by 30cm film strip. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
4.16 XR-QA2 dose response curves from Giaddui, Tomic and Lillo. Each
curve was obtained from a polychromatic source with 120kVp. . . . . . 89
4.17 Re-measured film strip in the centre of the TG111 phantom on the OBI
system. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
4.18 Re-measured film strip in the centre of the TG111 phantom on the XI
system. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
4.19 Three strips measured in succession on the XI system to evaluate tube
warm up on film response. The strips were measured in order S1-S3
with no CBCT scans acquired prior to the measurements. Also shown
is the Farmer chamber dose profile. . . . . . . . . . . . . . . . . . . . . 93
4.20 Three additional strips S4-S6 measured in succession on the XI sys-
tem after the X-Ray tube had warmed up. Also shown is the Farmer
chamber dose profile. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
LIST OF FIGURES ix
4.21 Film profile in the centre of the TG111 phantom for a OBI Pelvis mode
CBCT scan and the profile normalised to the central ionisation chamber
measurements taken prior to the change in X-Ray tube output. Error
bars represent the observed ±4.5% variation in the OBI film profiles. . 95
4.22 Film profile in the centre of the TG111 phantom for a XI Pelvis mode
CBCT scan and the profile normalised to the central ionisation chamber
measurement. Error bars represent the observed ±10% variation in the
XI film profiles. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
Investigation of the radiation dose from Cone Beam CT
for Image Guided Radiotherapy: A Comparison of
Methodologies
Jarryd Buckley




Image guidance is now an integral component of radiation therapy. It allows visual-
isation and verification of the target volume and surrounding structures during the
course of treatment allowing for tighter dose margins and subsequently better treat-
ment outcomes. This thesis will focus on evaluating the radiation dose from one image
guidance modality, kV cone-beam computed tomography (CBCT).
The first section of this thesis compares four alternative methodologies for quanti-
fying kV CBCT dose; the Cone-Beam Dose Index (CBDI), the International Atomic
Energy Agency Report 5 recommended methodology (IAEA) and the American Asso-
ciation of Physicists in Medicine Task Group 111 approach (TG111) with the current
methodology, the Computed Tomography Dose Index (CTDI). The methodologies
were evaluated for two kV CBCT imaging systems, the Varian Clinacr iX On-Board
Imager (OBI) and Varian TruebeamTM X-Ray Imager (XI). Dose measurements were
taken in a CTDI cylindrical Poly-Methyl Methacrylate (PMMA) phantom using a
Pencil type ionisation chamber with a sensitive length of 100 mm for the CTDI, CBDI
and IAEA methods. The TG111 method used a custom PMMA phantom constructed
in-house with the same radial dimensions as the CTDI phantom but increased in length
from 16 cm to 46 cm. Measurements were taken using a Farmer ionisation chamber
with a 2.4 cm sensitive length.
The methodologies were evaluated for clinically relevant scan modes on each imag-
ing system. Pelvis, Thorax, High Dose, Low Dose and Standard Dose Head protocols
were evaluated on the OBI system and Pelvis, Pelvis Obese, Thorax and Head pro-
tocols on the XI system. The TG111 method gave the highest dose for all the scan
modes across both OBI and XI systems, followed by CBDI, IAEA then the CTDI. The
Pelvis scan measured the highest dose across the methodologies for OBI with values
of 21.199 ± 0.014 mGy, 19.381 ± 0.029 mGy, 18.343 ± 0.002 mGy and 9.408 ± 0.029
mGy for TG111, CBDI, IAEA and CTDI respectively. The Pelvis Obese mode on the
XI system delivered the highest dose of all the scan modes with 48.529 ± 0.012 mGy,
44.390 ± 1.475 mGy, 32.295 ± 0.017 mGy and 20.743 ± 1.475 mGy for TG111, CBDI,
IAEA and CTDI methods.
The two imaging systems were compared for Pelvis, Thorax and equivalent Head
protocols. The OBI system gave a higher overall dose than XI. The Pelvis scan was
higher for the OBI by 2.95 mGy and Thorax OBI higher by 1.42 mGy from the TG111
method. For Head scans, the OBI also gave the higher dose with 4.605 ± 0.003 mGy
compared with 3.527 ± 0.002 mGy on XI from the CBDI method.
The effect of beam width was also investigated. Each methodology was evaluated
on the OBI systems Pelvis mode for beam widths from 2 cm to 40 cm. The TG111
and CBDI methods both approached a limiting value for increasing beam width, with
the TG111 being higher than CBDI by 2.258 mGy at 40 cm beam width. The IAEA
method plateaued at 15 cm beam width, measuring 18.545 mGy and dropping to
18.260 mGy at 40 cm beam width. The CTDI reached a maximum of 14.246 mGy at
10 cm beam width then decreased for increasing beam width falling to 5.047 mGy at
40 cm.
The Integral Dose (Etot), a term from the TG111 which describes the total energy
absorbed in the phantom, was determined for the Pelvis and Thorax modes on the
OBI system, and the Pelvis, Pelvis Obese and Thorax modes on the XI system. The
measured values were 445.69 ± 4.46 mJ and 128.89 ± 1.29 mJ for Pelvis and Thorax
OBI, and 462.41 ± 4.62 mJ, 999.81 ± 10.00 mJ and 114.49 ± 1.15 mJ for Pelvis, Pelvis
Obese and Thorax XI. The integral dose was also evaluated for beam widths ranging
from 2 cm to 40 cm. The integral dose increased linearly with beam width. Etot
increased by 822.49 mJ and 237.75 mJ for Pelvis and Thorax OBI modes respectively.
For XI Etot increased by 821.09 mJ, 1,775.38 mJ and 203.30 mJ for Pelvis, Pelvis
Obese and Thorax modes.
Dose profiles of the OBI and XI Pelvis modes were measured in the TG111 phantom
using the Farmer chamber and XR-QA2 GafchromicTM film. Both the OBI and XI
profiles extended beyond the collimated beam width at isocentre, with the Farmer
chamber measurements only falling to 62% and 58% of the maximum dose at the
collimated beam edge for OBI and XI systems respectively. The dose in the centre
of the beam was 3.2 mGy higher for the XI system compared with OBI, however the
difference decreased to 1.2 mGy at ± 12 cm. The film dose was higher than the Farmer
chamber measurements by 0.302 cGy for OBI and 0.245 cGy for XI at the centre of
the beam. Several factors were considered for the difference between the ionisation
chamber and film but no specific factor could be attributed to the variation.
CTDI measurements were taken in the TG111 phantom using normalised film strips
with sufficient length to capture the full dose profile and the results compared to the
methodologies. The CTDIwfilm was calculated to be 20.47 ± 0.71 mGy for OBI and
21.28 ± 0.44 mGy for XI. These were in good agreement with the TG111 protocol
values of 21.20 ± 0.01 mGy and 22.42 ± 0.01 mGy respectively. The agreement be-
tween CTDIwfilm and TG111 validated the TG111 method as a accurate representation
of CTDI with sufficient detector and phantom length. The result also validated the
CBDI as a good approximation to the CTDI using the existing CTDI100 phantom and
100mm Pencil ionisation chamber.
This thesis provides a quantitative comparison between four methodologies on two
commercial kV CBCT imaging systems for quantifying dose, and the effects of beam
width on dose and total deposited energy. The findings may assist clinical physicists
in choosing the appropriate scan parameters and frequency of CBCT acquisitions to
optimise the benefits of image guidance while limiting additional dose and in selecting
an appropriate methodology for quantifying the output from kV CBCT systems.
KEYWORDS: Cone Beam Computed Tomography, Radiotherapy, Image Guided
Radiotherapy
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In recent years there has been rapid development of modulated dose delivery methods
in radiotherapy such as Intensity Modulated Radiation Therapy (IMRT), Volumet-
ric Modulated Arc Therapy (VMAT) and Tomotherapy. With these new methods
the prescribed treatment dose can be delivered to the target with a high degree of
conformity while minimising the dose to healthy tissue.
However these techniques cannot be utilised to their full potential without adequate
verification of patient set up. The use of modulated delivery gives highly conformal
dose with steep dose gradients, so any variation in patient set up or movement can lead
to significant variation in dose delivered to both the tumour and surrounding tissue.
To verify patient set up with the required precision, Image Guided Radiation Ther-
apy (IGRT) is being utilised. Traditionally, position verification was performed with
the MV treatment source and an electronic portal imaging device (EPID) or film placed
opposite the treatment beam and beneath the patient. However at these MV energies
the inherent Compton scatter results in poor soft tissue contrast, limiting reference
points within the body to higher Z tissue such as bone, or internal fiducial markers. To
resolve this many LINACs now have a built in kV imager which can produce images
with improved soft tissue contrast to correct for internal organ motion and patient
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set up errors. Examples include the On-Board Imager (OBI) and the Truebeam X-
Ray imaging system (XI) of Varian Medical Systems (Palo Alto, CA) and the X-ray
Volumetric Imager (XVI) of Elekta Synergy (Crawley, United Kingdom).
These devices consist of a kV X-ray source and an amorphous silicon detector
mounted to the LINAC gantry on extendable robotic arms 90 degrees to the treatment
beam. These devices can aquire 3D cone-beam CT (CBCT) images of the patient
typically within 60 seconds. Volumetric images of the patient can be obtained in a
single rotation of the gantry and registered with the radiotherapy planning CT to
check for positional errors and make corrections as necessary with a high degree of
accuracy [1] [2].
Currently, imaging dose is largely omitted from treatment plans since it’s typically
two orders of magnitude smaller than the therapeutic doses, typically of 1-2 Gy for
a whole treatment schedule or 1-20 cGy for a single scan [3, 4, 5, 1, 6, 7, 8]. How-
ever, during an imaging procedure large portions of the body are irradiated, including
radiosensitve structures such as lung, breast, thyroid and reproductive organs. Bone
structures also receive higher doses at kV energies due to increased photoelectric effect
and their high atomic number Z.
Each clinic has its own protocols for frequency of CBCT depending on tumor site
and experience in expected daily shift. A typical CBCT might be once per day for
the first week then once per week. For Stereotactic Ablative Radiotherapy (SABR) at
least two CBCTs are performed in many centres and often three or four per fraction,
i.e one CBCT mid fraction. During a treatment of 30-40 fractions the imaging dose
has been shown to be significant [9, 1] and could lead to an increased risk of a patient
developing a secondary primary malignancy [10]. Therefore a method for quanifying
the imaging dose is necessary to evaluate any increased risk to the patient and make
an informed decision on the trade off between imaging dose and position verification.
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Clinically, the current CTDI paradigm for defining fan-beam CT dose does not
give an accurate estimate of the dose delivered to the patient from daily imaging,
particularly for the wide-beam scanning such as CBCT where beam widths can be in
excess of 40 cm [11]. Three alternative protocols have emerged in recent years which
attempt to better quantify the imaging dose for wide beam scanning [12, 11] however
it is not clear if these new methods offer a better representation of patient dose.
1.0.1 Research Aims
This thesis aims to address the following aspects of CBCT dosimetry:
• Evaluate and compare the current CTDI protocol with three alternate method-
ologies: the Cone-Beam Dose Index (CBDI) adapted for wide beam scanning
[13], the International Atomic Energy Agency Report No. 5 (IAEA) suggested
approach for wide beam dosimetry [11] and the American Association of Physi-
cists in Medicine Task Group 111 methodology (TG111)[12].
• Evaluate and compare methodologies for varying beam width, specifically for
clinical settings and compare between the listed protocols, and
• Compare dose between two Varian imaging systems: the OBIr on the C-Series




Radiotherapy is the use of ionising radiation for the treatment of cancer. It may be used
as an adjuvant therapy with surgery and or chemotherapy, as an ablative treatment
for locally advanced inoperable cancers or for palliation of advanced incurable disease.
Radiotherapy in combination with surgery and or chemotherapy has been shown to
improve local tumor control for a number of tumor types [14, 15, 16].
Radiotherapy may be delivered in 3 ways;
• external beam therapy through the use of a high energy linear accelerator or
orthovoltage and kilovoltage machines for superficial tumors,
• encapsulated sources which are placed within the patient either temporarily
such as in High Dose Rate brachytherapy or ‘permanently’ for Low Dose Rate
brachytherapy, and
• unencapsulated sources for targeted radionuclide therapy where the radioactive




For the purpose of this thesis, only external beam therapy with X-rays will be
discussed.
2.1.1 External Beam Therapy
The most common modality in radiotherapy is external beam therapy. For deep seated
tumors this requires mega voltage (MV) photons. These photons are generated and
delivered to the target using a linear accelerator or LINAC as shown in 2.1.
Figure 2.1: Truebeamr LINAC is capable of delivering MV X-Ray and electron therapy
as well as IGRT via its X-Ray imaging unit. Varian Medical Systems c©
Generally speaking, clinical LINACs deliver radiotherapy as follows. Electrons
generated from an electron gun are accelerated in a waveguide under microwave power
to relativistic velocities. The electrons are then bent through a bending magnet onto
a tungsten target producing MV photons through the Bremsstrahlung process. The
beam is then shaped and filtered by a set of collimators and a flattening filter to
reduce out of field scatter and flatten the beam profile. The field is then shaped by
a secondary set of collimators (or jaws) and a set of multi-leaf collimators (MLC) to
create fields of varying intensity. A detailed description of external beam radiotherapy
can be found in the literature [17].
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2.1.2 Interactions of kV Ionising Radiation
2.1.2.1 Interactions of Dose Deposition
With the exception of imaging with the MV treatment beam, imaging of the patient
during the course of radiotherapy occurs in the kilovoltage (kV) energy range, typically
between 70 kV and 150 kV. At these energies, the dominant interactions within the
body are Compton scattering and photo-electric absorption as shown in figure 2.2.
Figure 2.2: Schematic diagram of dominant photon interactions vs incident photon
energy. For energy ranges typical of imaging and radiotherapy (above 80-100 keV),
the Compton and photoelectric effects are the dominant interactions, and the only
interactions for imaging energies as pair production doesn’t occur in the kilovoltage
energy range. Also visible is the increased contribution of photo-electric absorption
with increasing atomic number of absorber. Source: Encyclopaedia of Occupational
Health and Safety. Fourth Edition
The dominant interaction of photons within tissue depends on their incident energy
and the composition of the material. For radiotherapy treatment, where MV energies
are used, the Compton effect dominates for most materials and dose deposition is rel-
atively consistent in soft tissue, muscle and bone [18]. However for diagnostic energies
in the kV range (such as for kV CBCT), the dominant interaction varies depending
on the energy and mass absorption coefficient of the material. For the lower energies
or higher Z materials such as bone, the photoelectric effect dominates due to its ≈
Z4
E4
dependance and hence absorption is greater. It’s this variation in Z which allows
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contrast in diagnostic images. However, regardless of which interaction the photon
undergoes, the result is ultimately a fast electron depositing energy in matter [18].
Compton Scattering
The Compton Effect occurs when an incident photon of energy Ep undergoes an elastic
collision with a free electron in the outer shell of an atom. For radiotherapy applica-
tions it is the dominant interaction, with it being the only interaction of significance
within tissue in the 200 keV to 2 MeV energy range [17]. During the Compton process,
some of the photon’s energy is transferred to the electron causing it to be ejected with
energy Ek.
Compton scatter reduces the signal to noise ratio (SNR) for imaging, particularly
for soft tissue. It presents the main challenge for CBCT reconstruction, especially for
MV CBCT where higher doses are required to achieve sufficient image quality [19] due
to detector quantum efficiency at higher energies producing increased noise. At kV
energies, the SNR is improved so kV CBCT requires less dose to achieve images of
sufficient image quality for IGRT as shown in figure 2.3.
Photoelectric Effect
The photoelectric effect is a phenomena by which a photon is completely absorbed by
a bound electron. If the energy of the photon is sufficient, the electron will be ejected
from the atom. The energy of the emitted electron depends on the incident photon
energy and any energy losses in escaping the atom.
If it is an inner shell electron that is ejected, then an outer shell electron will
replace it, emitting a photon with energy characteristic of the energy gap between
the electron shells or characteristic X-rays. However, since most tissue contains low-Z
elements the energy of such photons is sufficiently small (carbon = 0.3keV) such that
they are locally re-absorbed [17].
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Figure 2.3: Quantum detection efficiency for kV and MV energies for flat-panel im-
agers. The QDE is higher for kV energies than for MV [19].
The high Z of bone causes higher photoelectric absorption and high contrast com-
pared with soft tissue in kV CBCT images. The higher absorption also causes higher
dose in the bone, reportedly three times the dose to soft tissue [20].
2.1.2.2 Bremmstrahlung Radiation and Characteristic X-Rays
X-Rays are created when the kinetic energy of electrons is converted to electromagnetic
radiation when decelerated by a target material. The process is known as Bremm-
strahlung radiation and is the source of X-rays for MV external beam radiotherapy
and kV imaging.
The energy is lost via coulomb interactions with the target nucleus, which causes
the electrons to decelerate and change direction with the loss of kinetic energy being
dissipated as heat and the production of an X-ray photon.
In addition to Bremmstrahlung emission, characteristic emissions are also pro-
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duced. These emissions arise when a high energy electron strikes a bound electron in
the target material. Provided the kinetic energy of the electron exceeds the binding
energy of the atomic electron, it can be ejected from the atom. The vacancy created by
the ejected electron is replaced by an electron from an outer shell with lower binding
energy, releasing a characteristic X-ray with energy equal to the difference between
the binding energies of the two shells. Characteristic X-Rays can also be produced
from Bremmstrahlung photons striking the filter.
Electron transitions can occur from multiple energy levels, giving rise to different
characteristic X-ray energies. The energy spectrum of 90 kVp electrons striking a
tungsten target is shown in figure 2.4.
Figure 2.4: Filtered spectrum of Bremmstrahlung and characteristic radiation from a
tungsten target for a 90 kV potential. Source: [21].
2.1.3 Dosimeters
The purpose of a dosimeter is to estimate the absorbed dose in the medium to which
they are placed. In radiotherapy they are used for determining beam profiles as well
as verification of dose deposition with treatment planning.
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With the exception of calorimetry, dose cannot be directly measured, but rather
some property of ionising radiation is exploited to obtain an output which can be
converted to dose.
An ideal dosimeter should:
-Give an accurate and precise (reproducible) measurements over a large measure-
ment range
-Have a low detection limit
-Be linearly proportional to the delivered dose as well as being dose rate indepen-
dent.
-Be equivalent to the tissue in which the dose is being determined, and;
-Have a good spatial resolution
In reality however, no dosimeter possess all these attributes. A particular dosimeter
should be carefully chosen for its appropriate application where its properties are most
suited to the task. In this thesis, ionisation chambers and radiochromic film are used
to measure kV CBCT dose. Both dosimeters are discussed below.
2.1.3.1 Film
Film dosimetry is one of the oldest methods for the detection of X-rays [17]. All films
provide a 2D pixel intensity map that with appropriate calibration can be converted
into a 2D dose map. In recent times conventional radiographic film has been phased
out in favor of digital radiography where real-time dosimetry can be performed and
records are not subject to deterioration over time or if exposed to light and/or humidity
[17].
Radiochromic film has been replacing radiographic film of late for its self devel-
oping and near tissue equivalence, with current film dosimetry in radiotherapy being
increasingly dominated by the use of Gafchromic film [22], which also has the benefit
of being independent of dose rate[23]. However for energies below 100 keV, the film
2.1. Radiotherapy 11
displays an energy dependency of ≈ 14 % [24, 25] while for energies below 40 keV
variations of as much as 170% have been reported [26] . For energies in the range
of 80-145 kVp typical of CBCT however, the variation in sensitivity has been shown
to be less than 5%[27, 28]. For a non-homogeneous kV source, the effective energy
of the beam is dependent on both the kVp and HVL which must be considered in
making an assessment on the response of the film. The use of radiochromic film in the
investigation of CT and CBCT has been previously investigated with good agreement
between film response and measured dose provided the film has been calibrated for
the given beam energy and quality[4, 29, 30].
2.1.3.2 Ionisation Chamber
The ionisation chamber is the most common dosimeter used in radiotherapy depart-
ments. It is considered the gold standard of dosimeters and calibration of any ra-
dioactive sources mostly use this dosimeter, which is traceable to a primary standard.
Schematically, an ionisation chamber consists of two electrodes in a gas (e.g. air)
volume where an electric field is induced. When ionising radiation enters the sensi-
tive volume it ionises the gas producing electrons and positive ions. These ions are
attracted to their respective electrodes by the electric field producing a current. The
measured current can then be converted to dose. A more rigorous description regard-
ing the operation and physics of the ionisation chamber is given by Metcalfe et. al.
[17].
At diagnostic energy levels (80-140 keV), ionisation chambers have very little en-
ergy dependance, and can be directly traceable to secondary (or primary) standards,
whereas other detectors, including film and solid state dosimeters are not similarly
traceable and need additional calibration steps to establish traceability. Due to their
availability in the clinic, ease of use and versatility in their application, clinical proto-
cols developed to measure radiation dose use some version of the ionisation chamber,
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such as the 100mm pencil ionisation chamber in the CTDI methodology [31] and the
smaller volume thimble chamber in the TG-111 methodology [12] for quantifying CT
imaging dose.
CBCT dose has also been investigated with small volume dosimeters such as
Thermo-luminescent Dosimeters and Metal Oxide Silicon Field Effect Transistors, with
good agreement to ionisation chamber measurements [5, 7, 32, 13, 1, 6, 33, 34, 35].
Their small size make these dosimeters useful for skin dosimetry and placement within
anthropomorphic phantoms for organ dose measurements during CBCT scans [13, 1,
9, 36].
2.2 Image Guided Radiation Therapy
With the development of modern treatment modalities such as Intensity Modulated
Radiation Therapy (IMRT) and Volumetric Modulated Radiation Therapy (VMAT)
which deliver highly conformal dose with steep dose gradients[37, 17, 38, 39, 40], accu-
rate verification of the position of the target volume and critical structures just prior
to treatment is required. Image Guided Radiation Therapy (IGRT) utilises imaging
technology in the treatment room to verify positional information prior to or during
treatment. IGRT systems allow widespread management of geometric variations in
patient set-up and internal organ motion. The clinical introduction of these guidance
systems has allowed the assessment and correction of patient positioning uncertain-
ties, revealed internal organ motion and deformation and is paving the way towards
advanced and adaptive radiation therapy [41]. By improving the geometrical accuracy
of radiation therapy, planning volumes can be reduced leading to improvements in
tumor control probability and reduction in toxicity or dose escalation with the same
toxicity. Image guidance may include ultrasound and in the future MRI, but the most
common modality is kV X-ray.
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2.2.1 Image Guidance Modalities
2.2.1.1 Electronic Portal Imaging Device
This imaging modality utilizes the linac MV treatment beam and a flat-panel detector
mounted on a retractable arm to acquire 2D images of the patient. The detector
consists of an amorphous silicon detector array overlaid with a fluorescent layer. Due
to the high energy, these images are of a poorer quality than other imaging modalities
from Compton effects. However it’s sufficient for detecting motion of bony structures
and internal fiducial markers. The use of the treatment beam for imaging purposes
is advantageous as no additional imaging system is required, and imaging dose may
be incorporated into the treatment planning. However it has been shown to give the
highest dose of any imaging modality. Ding et. al. compared 50% DVL volumes for
several organ sites and found MV imaging dose ranged between 3-8 cGy compared
with 0.04-1.6 cGy and 0.07-0.12 cGy for kV-CBCT and kV radiograph for the same
anatomical structures respectively [42].
2.2.1.2 kV Radiograph
These images are acquired via the linac mounted imaging device consisting of a kV
X-ray source and flat panel detector. Two orthogonal images are taken for patient
position verification. kV radiographs have been shown to give the lowest dose of the
listed modalities [42].
2.2.1.3 Fan-Beam CT
Unlike the other imaging modalities, FBCT utilizes a fan-beam geometry to acquire
images analogous to a conventional CT scanner. The X-ray source is coupled to a
detector array 180 degrees from the source which both rotate around the patient.
MV FBCT images may also be acquired using the treatment beam of the tomother-
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apy treatment machine such as the Hi-Artr system from Accuray and a conventional
CT detector (Xe filled ionisation chamber array). Beam energy is reduced from 6 MV
to 3.5 MV and pulse repetition frequency reduced to minimise dose [17]. MV FBCT
allows for easy comparison to planning CT and produces less dose than multi-slice
CT scanning [9]. The dose from MVCT has been reported and is typically 1 cGy
per scan. These scans taken on a daily basis during a course of breast radiotherapy
have been shown to increase dose to controlateral breast by 28 cGy and 22 cGy to the
contralateral lung[43].
2.2.1.4 MV CBCT
MV CBCT images are acquired using the MV treatment beam and existing EPID
device in a rotation around the patient. Unlike FBCT the beam width for CBCT is
in the order of 20 centimeters (cm) and an image can be acquired in a single rotation
of the X-ray tube. It has been reported that MV CBCT images acquired on a linac
are of high enough quality for patient alignment [44] however generally with a higher
dose than kV CBCT [17, 42, 13, 45, 9].
2.2.1.5 kV CBCT
kV CBCT imaging is typically acquired with a gantry mounted kV imaging device
such as the Varian OBI or Elekta XVI. In both cases a kV X-ray source and flat-panel
detector are mounted on the gantry 180 degrees to one another and orthogonal to the
treatment beam. As with other 3D modalities the system rotates around the patient
to acquire CBCT images. It has been shown that kV CBCT results in a lower dose
to the patient compared with MV flat-panel imaging with superior image quality[42,
13, 45, 9]. However the image quality for kV CBCT is poorer than conventional
fan-beam CT and delivers a higher dose [1, 9], with the exception of multi-slice CT
which delivers more dose than kV CBCT [6]. Both MV and kV CBCT are based on
2.2. Image Guided Radiation Therapy 15
treatment isocentre, so for clinical implementation calibration procedures are required
to account for component sags and flexes from the weight of the system on the gantry
[46].
The relative dose delivered from each of the imaging modalities are summarised in
table 2.1.




MVCT Tomo - - - - 1.1-3.7
MV EPID 4.3-4.8 3.3 3.5
MV CBCT 0.08 (brain) 0.13 6.35
kV CBCT 0.04-0.06 1.0-1.6 0.2-0.4
kV Planar 0.12 0.07 0.07
Table 2.1: Summary of doses in cGy from imaging modalities used in radiotherapy
[42, 43, 47].
2.2.2 kV Imaging System
LINAC mounted kV imaging systems such as Varians OBIr, Truebeam XIr and the
Elekta XVIr consist of a kV X-ray generator, kV X-ray tube, beam collimator and
filters and a kV norm chamber [48, 49, 50]. The system is mounted on a retractable
arm which houses the high-voltage and oil-cooling cables for the X-ray tube. 180
degrees to the treatment beam is the kV imager, also on a retractable arm. The flat-
panel imager detects low dose X-rays from the kV source and can acquire fluoroscopic
and kV digital radiographic images as well as CBCT. The OBI unit mounted on a
Varian Clinac IXr accelerator is shown in figure 2.5.
The kV system shares the same isocentre as the MV treatment beam. As such,
online corrections can be made to patient set-up with remote couch movement.
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Figure 2.5: Varian Clinic IXr with OBI imaging system. The X-ray tube and flat-
panel detector are mounted to the gantry 180 degrees to one another on retractable
arms which are extended for kV imaging as shown. Courtesy: www.Varian.com
2.2.2.1 kV Delivery System
The kV X-ray generator is located in the stand and delivers the high-voltage power
supply to the X-ray tube. The generator also monitors and controls performance of
the tube such as temperature and oil pressure as well as tube current, voltage and
exposure time.
The kV X-ray tube is mounted on the left extendable source arm and provides the
kV X-rays via the production of Bremsstrahlung radiation and characteristic X-rays.
A simple diagram of the GS-1542 X-ray tube used by the XI imaging system is shown
in figure 2.6.
The tube consists of a cathode that supplies the electrons and an anode target
1-2cm from the cathode that rotates to dissipate heat. The anode and cathode are
encased in a tube housing to provide protection from radiation leakage and encapsulate
the cooling oil [48].
Electrons from the cathode are accelerated by an electric field between the cathode
and anode, which is controlled by the X-ray generator to produce the required photon
energy. For example, to generate 120 kVp photons, 120 kV will be applied between
the cathode and anode. This will accelerate electrons to 120 keV since kinetic energy
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Figure 2.6: GS-1542 X-ray tube schematic from the XI imaging system. Source: [48]
is the product of electrical charge (1 eV for an electron) and potential across the field.
Upon striking the target, photons are released via the Bremmstrahlung process along
with characteristic X-rays as described in section 2.1.2.2.
2.2.2.2 Collimation and Filters
The kV delivery system uses a series of collimators and filters to adjust field size and
modify the energy spectrum. An overview of the collimation system on the XI system
is shown in figure 2.7.
The beam first passes through inherent filtration from the exit window (C) which
removes low energy photons from the spectrum before passing a set of primary lead
collimators that limit beam scatter by restricting the maximum field size of the beam
(J). The norm chamber sits next to the primary collimators and monitors pulse by
pulse fluctuations in the secondary radiation of the kV beam during CBCT acquisitions
(D).
The image size is regulated by the collimators (K). The collimators consist of two
sets of lead blades, one set to regulate field size in the X direction and the other in the
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Figure 2.7: kV collimation and filtration on the XI imaging system. Source: [48]
Y direction. The blades move independently of each other allowing for asymmetric
field shapes to limit exposure to the areas that require imaging.
An improvement that was made from OBI to the XI system was the addition of a
0.89 mm titanium foil filter to harden the beam by absorbing low-energy photons and
subsequently reduce the imaging dose and improve image quality (L) [48].
Bow-tie filters non-uniformly shape the kV beam to improve the quality of CBCT
projections (E). They reduce skin dose to the patient, reduce X-ray scatter to improve
image quality and enable larger imaging fields than the maximum width of the de-
tector for CBCT acquisitions. The filters are constructed from aluminum and vary in
thickness between 2 mm and 28 mm.
For small fields the symmetrical full bowtie filter is used while for large field sizes
half bowtie filter produces an asymmetric field in the x-y plane, as shown in figure 2.8.
The bow-tie filter is in-built into the XI system and will insert the appropriate
filter for the chosen scan, while the filter is applied to the kV generator manually for
the OBI system.
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(a)
(b)
Figure 2.8: (a)Bow-tie filters used for CBCT filtration. The size of the FOV dictates
the filter with small FOV head scans using the full-fan(A) while larger FOV scans use
the half-fan(B). Source: [48]. (b)Diagrammatic representation of full-fan vs half-fan
scanning. Full-fan scanning (a-partial scan)(b-full scan) is used for scanning smaller
targets. The collimation is symmetric and the beam is centred on isocentre. Half-fan
scanning (c)(d) acquires a larger FOV using an asymmetric beam offset from centre.
Source: [30]
2.2.2.3 Flat Panel Detector System
Real time imaging of the patient for image guidance is possible through flat-panel
Thin-Film Transistor (TFT) array detectors which convert the X-ray intensities to an
electric readout. The PaxScan 4030CB and MV IDU 20 model detectors are used by
Varian for kV and MV imaging respectively [48].
The detector consists of an array of individual display elements arranged in a
matrix. They are constructed of amorphous Silicon etched to deposit the necessary
electrical components and connections. Each individual detector element contains a
TFT, charge collection electrode and a storage capacitor as shown in figure 2.9.
The TFT is an electronic switch containing three connections: the source, drain and
gate. Gate and drain lines connect the gate and drains of each detector element along
a row. X-ray imaging devices with TFT’s can be separated into two categories: those
which incorporate a photoconductor to produce electrical charges on the detection of
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Figure 2.9: Schematic overview of the flat panel TFT array detector. Each detec-
tor element consists of a TFT, a charge collection electrode and a storage capacitor.
Courtesy: www.arosystems.com.au
an X-ray, known as direct conversion, and those which use a scintillator material, such
as CsI or Gd2O2S, to produce visible photons which are then collected and converted
to charge by the charge collection electrode via the photoelectric process and stored
in the storage capacitor. Both processes are illustrated in figure 2.10 [51].
Figure 2.10: Large area active matrix array for X-ray TFT detector with (a) direct
conversion using a photo conductor layer with pixel electrodes and (b) indirect con-
version using a phosphor layer and photo diodes. Source: [51] figure 7.9 page 173.
During the irradiation the TFT switch is closed, allowing charge to be accumulated
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and stored in each capacitor. Following the exposure the gate line to each detector
row is turned on sequentially, allowing the stored charge to flow through the drain
line and to the connected charge amplifiers. The charge amplifiers amplify the charge,
convert it to a proportional voltage and digitise the voltage level to produce a grey
scale value for each detector row. The process is repeated for each row to read out the
array [21].
2.3 Radiation Dose from kV CBCT Image Guided
Radiotherapy
The imaging dose received as part of radiotherapy procedures has previously been
given little consideration in planning as it was considered negligible in comparison to
therapeutic dose. However with the development of more advanced imaging procedures
during image guided therapy such as CBCT, imaging dose can not be considered
negligible and staff should be aware of the magnitude of dose delivered, particularly
after claims of 2-3 Gy from CBCT imaging alone during a course of radiotherapy was
reported by Spezi et.al.[52, 53].
Many studies have sought to investigate the dose delivered from CBCT imaging
with varied results [54]. Typically CBCT dose studies use phantoms such as cylindrical
or elliptical designs or Anthropomorphic phantoms [1, 55, 5, 13, 35, 56, 36, 9, 7, 4].
CBCT dose has also been calculated using collected beam data through Monte Carlo
methods such as EGSnrc and Geant4 [3, 20, 57, 58, 59, 53, 42], and treatment planning
systems (TPS) such as Philips Pinnacler TPS [60] . Effective doses from CBCT head,
thorax and pelvis scans are summarised in table 2.2, and absorbed dose studies in table
2.3. The effective dose is calculated from the summation of doses to irradiated organs,
scaled by tissue weighting factors usually taken from International Commission on
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Radiological Protection (ICRP) report 60 [61] or more recently report 103, where some
weighting factors were revised [62]. A more detailed description of effective dose as
defined by the ICRP can be found in section 2.4.3.1. The relationship between effective
dose for diagnostic doses due to weighting factors has been previously investigated [63].
Study Head Scan
(mSv)
Thorax (mSv) Pelvis (mSv) Phantom Dosimeter
Sawyer et. al.[34] 2.83 ± 0.03 15.3 ± 0.3 13.4 ± 0.5 Anthropomorphic TLD
Hyer et. al. (XVI)[36] 0.04 * 7.15 * 3.73 * Anthropomorphic Fibre Optic Coupled
Hyer et. al. (OBI)[36] 0.12 * 1.82 * 4.34 * Anthropomorphic Fibre Optic Coupled
Kan et. al. (std dose)[1] 10.26 ± 0.46 23.56 ± 0.35 22.72 ± 0.29 Anthropomorphic TLD
Kan et. al. (low dose)[1] 2.10 ± 0.08 5.23 ± 0.122 4.89 ± 0.163 Anthropomorphic TLD




4.05 * Anthropomorphic TLD
Cheng et. al.[64] 1.65 ± 0.01 – 8.21 ± 0.04 Anthropomorphic TLD
Gu et. al.[59] 8.54 * – 6.25 * VIP-man phantom Monte Carlo Simulation
Table 2.2: Effective dose per scan kV CBCT for head and neck, thorax and pelvis
protocols. (std dose) and (low dose) refer to different scan settings, with low dose
using a lower mAs. The order of magnitude variation between studies is likely due to
older scan algorithms having much higher exposures compared with newer versions.
Studies which did not provide an uncertainty for their values are indicated by *.
The effective dose values vary within a wide range of 0.04-10.26 mSv for head and
neck imaging and 1.82-23.56 mSv for pelvis and thorax imaging. These varied results
can be attributed to several factors such as variations in anatomical site, measured
dose, relative tissue weighting factor used, a low or high dose imaging protocol and
make of the imager which may influence the size of the imaged volume and filtration
systems including bow tie filters. Different software versions may have been used,
with the newer versions tending to reduce concomitant dose while maintaining similar
image quality[54].
Of particular interest is the dose received by organs most sensitive to radiation
such as the eye or the spinal cord. Monte Carlo studies have shown the dose to the
eye, spinal cord, brain and cervical vertebrae can be as high as 80, 60, 50 and 180
mGy respectively from a head and neck CBCT scan [3]. For bone, doses as high as
250 mGy were predicted due to the increased photoelectric effect. Abdominal scans
showed mean doses of 30 and 70 mGy to the prostate and femoral heads respectively
[3, 20]. By comparison, Hyer et. al. measured doses in an anthropomorphic phantom
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and found only 1.07 mGy for the lens and 0.70 mGy for the brain following a head
scan, while following a pelvic scan the prostate received 27.63 mGy suggesting some
variation between simulation and measurement [36]. The Hyer study also reports its
measurements were taken with a more recent version of the OBI software which reduces
tube current and uses a 200 degree gantry rotation for head scanning to reduce dose
to the eye [36].
Patient based CBCT dose studies form 20% of the literature [54] and generally
employ TLD’s or something similar to measure skin dose, which ranged from from a
fraction of a cGy to 7 cGy [5, 13, 35, 56]. Dose to the rectum has also been measured
in vivo and indicate 2-3 cGy per CBCT acquisition [45, 65].
Out of field doses from CBCT imaging are of some concern, particularly when
combined with head leakage and scatter from the treatment beam. Perks et. al. mea-
sured the peripheral kV-CBCT dose and compared with IMRT treatment alone and
found the two were of the same order of magnitude [33]. Qui et. al. also investigated
the peripheral kV-CBCT dose with head leakage and scatter through Monte Carlo
simulation, concluding the peripheral CBCT dose is of the same order of magnitude
as LINAC leakage and an order or magnitude smaller than IMRT Arc therapy scatter
dose [66].
2.3.1 Computed Tomography Dose Index
The current paradigm for characterising radiation dose in CT scanners is based on
the computed tomography dose index (CTDI) introduced over 30 years ago [31]. The
CTDI quantifies the radiation output of the CT scanner, giving a dose index which
relates to the phantom used, mAs and kV for quality assurance purposes. However it
does not represent the patient dose [67].
As outlined by Shope et. al., the average dose in the centre of a multi-slice CT
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Study Phantom Dosimeter Dose (mGy)
Hu 2014 Cylindrical PMMA 45cm
long
0.6cc Thimble chamber, AAPM
TG111 Formalism
22.70 (Pelvis)
Hu 2014 Cylindrical PMMA 15cm
long
100cm pencil chamber, CTDI For-
malism
18.06 (Pelvis)
Hu 2014 Cylindrical PMMA 15cm
long
100cm pencil chamber, IAEA For-
malism
15.88 (Pelvis)
Hu 2014 Cylindrical PMMA 45cm
long
0.6cc Thimble chamber, AAPM
TG111 Formalism
28.11 (High Quality Head)
Hu 2014 Cylindrical PMMA 15cm
long
100cm pencil chamber, CTDI For-
malism
27.10 (High Quality Head)
Hu 2014 Cylindrical PMMA 15cm
long
100cm pencil chamber, IAEA For-
malism
21.49 (High Quality Head)
Hu 2014 Cylindrical PMMA 45cm
long
0.6cc Thimble chamber, AAPM
TG111 Formalism
5.49 (Standard Dose Head)
Hu 2014 Cylindrical PMMA 15cm
long
100cm pencil chamber, CTDI For-
malism
5.53 (Standard Dose Head)
Hu 2014 Cylindrical PMMA 15cm
long
100cm pencil chamber, IAEA For-
malism
4.28 (Standard Dose Head)
Ding 2013 Cylindrical PMMA 15cm
long
100cm pencil chamber, IAEA For-
malism
4.28 (Standard Dose Head)
Kan 2007 Anthropomorphic phan-
tom
TLD Skin dose measurement 67 (Standard Dose Head)
Kan 2007 Anthropomorphic phan-
tom
TLD Skin dose measurement 64 (Thorax)
Kan 2007 Anthropomorphic phan-
tom
TLD Skin dose measurement 54 (Pelvis)
Spezi 2011 Patient data-skin dose Monte Carlo 20-60 (Pelvis-femoral
heads)
Spezi 2011 Patient data-skin dose Monte Carlo 25-50 (Thorax-PTV)
Spezi 2011 Patient data Monte Carlo 300 (Head and Neck-mean
dose)
Hyer 2010 Cylindrical PMMA 15cm
long
100cm pencil chamber, CTDI For-
malism
0.98 (Head XVI)
Hyer 2010 Cylindrical PMMA 15cm
long
100cm pencil chamber, CTDI For-
malism
16.62 (Thorax XVI)
Hyer 2010 Cylindrical PMMA 15cm
long
100cm pencil chamber, CTDI For-
malism
24.13 (Pelvis XVI)
Hyer 2010 Cylindrical PMMA 15cm
long
100cm pencil chamber, CTDI For-
malism
5.17 (Head OBI)
Hyer 2010 Cylindrical PMMA 15cm
long
100cm pencil chamber, CTDI For-
malism
6.14 (Thorax OBI)
Hyer 2010 Cylindrical PMMA 15cm
long
100cm pencil chamber, CTDI For-
malism
21.57 (Pelvis OBI)
Wen 2007 IMRt QA phantom, 30cm
oval
TLD’s 30-60 AP skin dose
Wen 2007 Rando Phantom TLD’s 100-110 (femoral heads)
Alaei 2010 Rando Phantom TLD’s 21-45 (Soft tissue regions)
Alaei 2010 Rando Phantom TLD’s 32-102 (In and near bone
areas)
Islam 2006 30cm diameter cylindrical
water phantom
MOSFET detectors 16 (centre position)
Islam 2006 30cm diameter cylindrical
water phantom
MOSFET detectors 23 (peripheral average)
Amer 2006 Cylindrical PMMA 15cm
long
100cm pencil chamber, CTDI For-
malism
1.6 (Head)
Amer 2006 Cylindrical PMMA 15cm
long
100cm pencil chamber, CTDI For-
malism
6.0 (Thorax)
Amer 2006 Cylindrical PMMA 15cm
long
100cm pencil chamber, CTDI For-
malism
25.0 (Pelvis)
Ding 2013 Patient CT data Monte Carlo 0.4-0.6 (Head-Eye 50%
dose)
Ding 2013 Patient CT data Monte Carlo 10-16 (Pelvis-Bladder 50%
dose)
Ding 2013 Patient CT data Monte Carlo 2-4.2 (Thorax-Heart 50%
dose)
Table 2.3: Summary of publications evaluating dose from kV CBCT imaging.
scan is mathematically equivalent to the single rotation dose profile per total beam
width integrated over (-L/2, L/2)[31], termed CTDI. Here L is the integration length
of the ionisation chamber along the z-axis, as illustrated in figure 2.11. Hence, average
dose for a multi-slice scan can be conveniently determined with a single rotation of the
X-ray tube. Typically the CTDI is measured with a 100mm length ionisation chamber
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symmetrically centered across the fan plane.
Figure 2.11: Diagram of axis for imaging. The axial plane is defined as the plane in
the x-y axis. Linac schematic courtesy of http://www.suggest-keywords.com







Where D(z) is the dose profile originating from a single axial rotation, the dose
being expressed as absorbed dose in air. n is the number of active acquisition channels
(detector rows) and T is the nominal slice thickness of each channel.
2.3.1.1 CTDI Phantom
The cylindrical CTDI phantom is constructed of Poly Methyl Methacrylate (PMMA).
The body phantom is 32 cm in diameter while the head phantom has a diameter of 16
cm. The phantom is 15 cm in length [68]. Both phantoms are shown in figure 2.12.
Both phantoms have five holes for CTDI measurements, one in the centre and four
on the periphery. Each hole not housing the pencil chamber holds a PMMA plug to
eliminate air gaps.
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Figure 2.12: Head and Body CTDI phantoms for CTDI measurements. The Body
phantom is 32 cm diameter and the head phantom 16 cm in diameter. Both phantoms
are 15 cm in length. The 100 mm pencil chamber is also shown. Source: www.ptw.de
2.3.1.2 CTDIw
The weighted CTDIw describes the average weighted dose in the axial plane. It is
calculated using 5 measurements from each position in the phantom, 1 in the centre
and 4 on the periphery. Each measurement is weighted according to its position within








This concept is only applicable for a series of contiguous axial scans or helical
scanning with a pitch of unity. For helical scanning with pitch not equal to unity, the
CTDIvol may be calculated.
2.3.1.3 CTDIvol
With the introduction of the helical CT scanner, volume CTDI or CTDIvol was de-
veloped and takes into account the effect of couch translation during irradiation and
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The CTDIvol represents the average dose in the central z-axis region of the scanned
volume equivalent to the integration length of the CTDI equation, defined by the couch
increment per rotation (helical) or couch incrimination in axial scanning.
2.3.1.4 Dose Length Integral and Dose Length Product
The dose length integral is, as the name suggests, the integration of the dose profile over
the scan length. This may be calculated via summation of point dose measurements
stepped through the beam [69] or via a long integrating dosimeter such as the 100mm
pencil chamber and a single rotation of the X-ray tube.
The dose length product (DLP) is an approximation of the total dose from an
entire CT examination and is calculated as follows:
DLP = CTDIw × scanlength (2.4)
Since the DLP gives an estimate of the total absorbed dose, it can potentially be
related to the effective dose which has been investigated for diagnostic CT [70].
2.3.1.5 Integral Dose Etot
Integral ‘dose’ Etot is defined by the AAPM Task Group 111 as the total energy
absorbed within the phantom measured in Joules[12]. It provides a simplified indicator
for patient risk and is derived from the volume and density of the phantom multiplied
with the planar average equilibrium dose Deq, which is defined in section 2.3.3.3.
Some definitions of the planar dose including the TG111 described below, determine
the planar dose in the CTDI phantom from uniform weighting of the central and
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peripheral doses based on a 1
R2
relationship where R is the phantom radius. However
it has been shown that the CTDIw weighted approach gives a better estimate of planar
dose [71]. The integral is then defined as:
Etot = ρπR
2LDeq (2.5)
where ρ is the phantom density, Deq is the radially averaged equilibrium dose and
L is the total scan length.
2.3.2 Limitations of CTDI
With advances in CT technology since the introduction of CTDI including helical scan-
ning and wide cone-beam scanning, the validity of the CTDI has become increasingly
limited [72]. Additionally, as trends towards wider collimation in the z-axis and longer
scan lengths continue, increased amounts of scattered radiation are not detected by
the 100mm pencil chamber resulting in underestimation of the dose [72]. It has been
suggested that integration lengths for CBCT should be greater than 300mm for beam
widths greater than 20mm to capture the full dose profile[73, 74].
When the CTDI is measured, both the primary beam and scattered radiation
within the phantom contribute to the measurement. In the IAEA Report No. 5, it’s
suggested that provided the actual beam width does not exceed 80mm at isocentre
and a focus to isocentre distance of 600mm, the primary beam width will not ex-
ceed the 100mm ionisation chamber for CTDI100 measurements[11]. However, the
scattered radiation field extends throughout the entire CTDI phantom and into the
surrounding air. Hence, the 100mm chamber (100mm scanning length) will not collect
all the scattered radiation and will underestimate the delivered dose, by as much as
40 to 50 percent compared to a 450 mm chamber, irrespective of beam width [12, 29].
Additionally, the phantom used in CTDI100 is of insufficient length to produce scatter
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equilibrium in the centre of the beam with approximately a 30 percent underestima-
tion relative to a phantom of sufficient length for scatter equilibrium [74, 29]. The
ratio of the CTDI100 to CTDI∞ quantifies the variation of the CTDI100 compared
with infinite phantom and detector length and is known as the CTDI measurement
efficiency.
The relevance of CTDI for Cone-Beam CT is particularly questionable. In CBCT,
the beam is sufficiently broad to image anatomy of interest in a single rotation without
table translation. Thus, the use of CTDI to quantify dose isn’t appropriate as it’s
defined as an integration over table translation of length L. CBCT scans are typically
broader than the 100mm active length of the chamber itself for pelvis and thorax
scanning modes. The beam also diverges to even greater widths due to scatter within
the phantom, so the chamber does not capture a large amount of the dose profile.
The literature also suggests that the CTDI concept breaks down due to beam non-
uniformity and the weightings of central and peripheral dose in CTDIw not being an
accurate representation of average dose across the volume [68].
2.3.3 Alternative Protocols for Wide-Beam Dosimetry
Due to the limitations of the CTDI to quantify dose from wide-beam CT scanners,
new alternative methods of determining the dose for these wide-beam scanners have
been investigated, typically by either increasing the length of the ionisation chamber to
capture the full dose profile or utilising a small volume detector to measure cumulative
dose in the centre of the phantom [75, 74, 76, 77]. This has resulted in three new
protocols being developed which give an alternative method of quantifying the imaging
dose for wide beam dosimetry.
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2.3.3.1 Cone Beam Dose Index
The Cone Beam Dose Index (CBDI) was introduced by Amer et. al. to give a better
estimate of the dose from wide-beam scanning using the existing 100 mm chamber and
CTDI phantoms [13].
The CBDI is representative of an average dose across the central 10 cm portion of







where D(z) was previously defined in (2.1) and L in this case representing the
chamber length of 100mm. The CBDIw is defined in exactly the same way as CTDIw
(2.2). The CBDIw can also be normalised to 100mAs by multiplying by 100 and
dividing by the exposure used to measure the CBDI. Some published dose values for











Amer et. al. [13] 4.3 3.8 5.5
Cheng et. al. [64] 5.1 – 4.3
Hyer et. al. (XVI) [36] 2.73 1.62 1.47
Hyer et. al. (OBI) [36] 3.57 2.34 3.17
Table 2.4: CBDIw studies for head, thorax and pelvis scans in mGy normalised per
100mAs. Normalised values provide a means of comparison between different imaging
systems with varying mAs.
The CBDI approach has been shown to give good agreement with CTDI measure-
ments taken with longer ionisation chambers that can measure the full profile from
wider beam scanning [78], making it a useful method for quantifying the dose output
from CBCT scanning using existing ionisation chambers and phantoms.
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2.3.3.2 IAEA Report No. 5
Due to the limitations of the CTDI for wide beam scanning, the International Atomic
Energy Agency (IAEA) recommended a protocol developed by the International Elec-
trotechnical Commission (IEC)[79]. The protocol is based on the relatively constant
efficiency of the CTDI100 to CTDI∞ for beam widths < 60mm, as shown in figure
2.13 [72].
Figure 2.13: CTDI100 measurement efficiency for a 32 cm PMMA phantom as a
function of scanning length for a 120kVp beam. Source [72]
The protocol suggests a two tiered approach. For beam widths < 60mm, the
standard CTDI100 should be applied. For longer scanning lengths, the CTDI100 is
determined for a reference beam width, recommended to be 20mm. This is then
scaled by the free in-air ratio of CTDI for the protocol and reference beam widths,
shown below (2.7).
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The protocol defines minimum scanning length of 100 mm for beam widths <
60mm and 20mm either side of beam width for beams > 60mm to ensure all the
primary beam is included in the CTDIfree−in−air measurement.
Since this protocol does not include scatter contributions it still underestimates
the dose in the central scan region compared to an infinite scanning and phantom
length CTDI∞. Abuhaimed et. al. [30] showed the underestimation to be ≈ 18 % in
the head phantom and ≈ 24 % in the body phantom for a clinical beam width of 198
mm. However, the efficiency remains constant across all beam widths beyond 40 mm,
verified by Monte Carlo simulations and measurements for wide beam CT and CBCT
as shown in figure 2.14 [30, 79]. By comparison, for the same conditions described
above, Abuhaimed showed the underestimation of the CTDI100 to be ≈ 55 % and ≈
56 % respectively.
2.3.3.3 AAPM Task Group 111
The TG111 report from the American Association of Physicists in Medicine (AAPM)
introduces a new method of determining CT dose following several studies investigating
an alternative dosimetry approach to wide beam scanning [75, 76, 77]. Its advantage
lies in its applicability to all CT scanner types [12]. Unlike the CTDI paradigm,
the TG111 method stipulates the use of a small volume dosimeter for a point dose
measurement at the centre of the scan length. The dose at the centre of the scan length
is formed from contributions by both the primary beam and scatter tails lying beyond
the primary beam. These measurements are taken for increasing scanning length
to determine the equilibrium dose Deq, where dose to the central region is maximum.
Further increases in scanning length will not increase dose at the centre of the phantom
as the scatter tails are sufficiently remote to make a negligible contribution. This scan
length for the equilibrium dose is the equilibrium scan length Leq. From this other
parameters may be determined such as equilibrium dose constant and equilibrium
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Figure 2.14: Efficiency of the IAEA method compared with CTDI∞ for head(a-b) and
body(c-d) phantoms for 200 and 360 degree rotations. Source: [30]
dose pitch product, which are independent of scanning parameters like scan length,
pitch and collimator width [12].
The dose at z=0 is characterised by both the equilibrium dose Deq and an approach
to equilibrium function h(L) which describes the increasing dose at z=0 with increasing
scan length (L) as shown in figure 2.15 and equation (2.9).
DL(z = 0) = h(L)×Deq (2.8)
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where;





Figure 2.15: Approach to equilibrium at the central and peripheral locations within a
body PMMA phantom measured with a farmer chamber. Also shown are the approach
to equilibrium functions with their respective coefficients. Source [77]
For CBCT, the protocol is simplified somewhat given there is no table motion or
pitch. The scan is acquired in a single rotation and scan length is determined by
collimation in the z-axis. Preliminary studies following the TG111 method have been
published showing an increased dose relative to the CTDI protocol, by as much as
40% compared with the vendor stated dose [80, 8]
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2.4 Low Dose Radiation and Secondary Cancer Risk
Due to advances in cancer treatment and earlier detection, cancer survival rates have
dramatically improved with 5 year survival rates in the US increasing from 50% to 66%
among adults and from 61% to 79% among children from 1975-79 to 1996-2002[81].
Although CBCT has not been in use clinically for sufficient time to evaluate increased
cancer risk due to imaging from patient data, many studies have investigated in-
creased secondary cancer risk from radiation exposure data and radiotherapy treat-
ments, which have out of field dose comparable to CBCT [82, 83, 84, 85]. These doses
have been linked to a statistically significant increase in secondary cancer risk [86].
The application of risk models to additional kV CBCT dose to asses increased risk
from imaging has also been investigated [87].
Our understanding of radiation induced cancers is limited to studies of atomic
bomb survivors, nuclear accidents, radiotherapy patients and occupationally exposed
radiation workers. Conclusions drawn from these studies are presumptuous however.
Underlying factors such as lifestyle or genetic pre-disposition may outweigh any in-
crease in risk of developing a secondary malignancy due to low doses of radiation,
particularly for patients already being treated for cancer. This is especially relevant
to low dose studies, such as imaging [88]. Quinn et. al. [89] reported an uncertainty
of 40% when estimating the Excess Absolute Risk (EAR) and Excess Relative Risk
(ERR) using the Preston method for kV CBCT imaging during breast radiotherapy.
2.4.1 Studies of Atomic Bomb Survivors
Life span studies of survivors from the atomic bombings of Hiroshima and Nagasaki
provide the best qualitative risk estimates for secondary malignancies following low-
LET radiation exposure to humans. Unlike studies of cancer patients, it includes
survivors of varying age, gender and received dose. All subjects are from a similar
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demographic and considered healthy at the time of the bombings. The studies included
enough members to be of statistical relevance, particularly for studying the effects of
low doses [90]. They also include enough people from the area of the bombings, but
not present at the time of the bombings or are believed to have received a negligible
dose to make an assessment of the risk of cancer incidence independent of demographic
influence. Studies based on follow up survival data from 1958 onwards form the basis
for dose-risk models and radiation protection guidelines [91, 92].
However the accuracy of the studies are limited by the models used to estimate
received dose, as well as tracking of survivors over time. As studies continue to be
published with longer follow up and improved dose estimates risk models will however
continue to improve [93].
From the survival data, Preston et. al. [93] determined Excess Relative Risk ERR
and Excess Absolute Risk EAR. The results took into consideration dose (d), age at
exposure (e), gender (s), age from birth (b), city (c), location at time of A-Bomb (l)
and attained age (a). λ0 is the background cancer incidence rate (zero dose assumed).
λ0(c, s, a, b, l)[1 + ERR(d, e, s, a)] (2.10)
λ0(c, s, a, b, l) + EAR(d, e, s, a) (2.11)
Dose-response relationships considered were linear, linear quadratic, quadratic,
linear threshold and a nonparametric model. The data indicated that a linear no-
threshold model best describes the dose response curve for low dose[93, 94].
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2.4.2 Secondary Cancer Risk from Radiotherapy Procedures
Unlike a cohort study, such as that of atomic bomb survival data where people of
varying lifestyle, age, genetic factors etc are exposed to varying doses [88, 93], stud-
ies of radiotherapy patients are of similar dose values and the risk of a secondary
cancer developing is usually higher. The relative risk of developing a secondary can-
cer following radiotherapy is inversely related to age of treatment and appears to
increase with time following radiotherapy [95, 96, 97]. Several studies have investi-
gated the onset of secondary cancers following radiotherapy for several cancer sites,
with cancers of the cervix and the prostate having the largest amount of follow up
data[96, 97, 95, 98, 99, 100].
A study of 104,760 survivors of cervical cancer found the majority of secondary
malignancies were observed within the pelvic region where the highest dose occurs,
including the rectum, vagina, vulva, ovary and bladder [97]. Increases in lymphatic
leukemia and cancers of the bone and kidney were also observed. A smaller amount
of cases were seen for moderate and lightly irradiated sites . An increased risk of lung
cancer was also observed, however this is thought to be more closely related to the
effects of cigarette smoking and the presence of human papillomavirus (HPV)[95, 96,
97].
Some debate exists on the risk, if any, of a secondary malignancy occurring as a
result of radiotherapy for prostate cancer [100, 101]. The associated risk of a secondary
malignancy following prostate radiotherapy is small, with Kendal et. al. suggesting
that there is no detectable risk associated with prostate radiotherapy [102]. Rather, an
increase in observed renal cancers (the most common secondary cancer site following
prostate therapy) being associated with other factors such as smoking. However when
considering all cancers following prostate radiotherapy compared with surgery alone,
Brenner et. al. [98] reported a small but statistically significant increase in secondary
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cancers, which Brenner attributes to radiation effects [101]. A 6% increase in risk of
solid tumor relative to surgery was observed, while increased relative risks reached
15% and 34% following 5 and 10 years follow up respectively.
2.4.3 Risk Models for Low Dose Radiation
As mentioned above, treatment with radiotherapy has been shown to increase the risk
of a secondary cancer to a statistically significant extent. Hence, it’s advantageous to
limit the dose received to normal tissue including OAR as much as possible during
treatment. This extends to the use of image guidance during treatment. Currently,
there are no epidemiological studies relating imaging and increased secondary cancer
risks, partly due to the lack of sufficient patients and follow up times for study but also
due to the low dose from the imaging relative to the treatment. Indeed, any increased
risk due to imaging may be negated by other factors as outlined above and a large
sample size is required for adequate statistics [103, 88].
In light of this, the only method available to quantitatively assess increased risk
from imaging is through the use of radiation-induced cancer risk estimation models[104,
62]. These models have been developed based on data obtained from radiation workers,
medical exposure data and atomic bomb survival data [93].
The difficulty with model based estimates is the uncertainty in the dose response
curve for low dose. Because of the low doses involved, to determine accurately the
shape of the response curve would require an impractical number of patients for an
epidemiological study to detect an increased risks since the excess risk is less for
smaller doses. Alternatively, low dose response may be predicted based on the more
easily obtained responses for higher doses. However such extrapolations are highly
presumptuous [90]. The limit of dose uncertainty has however reduced over time.
Land et. al. defined low dose as below 2,500 mSv in 1980 [90] while more recently
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Brenner et. al. defines uncertainty in dose risk estimates to be below 50 mSv [94].
From atomic bomb survival data, a linear relation of dose to excess risk for the
range of 5cGy-2.5Gy is observed. However, the use of a linear response for dose values
below this is presumptuous due to underlying biological mechanisms that could lead to
an under or overestimation of risk compared to the linear no threshold approximation
[94]. Potential responses are demonstrated in figure 2.16.
Figure 2.16: Schematic diagram of different possible radiation risks extrapolated
from measured radiation risk to low doses. Curve a-linear extrapolation, curve
b-downwardly curving, curve c-upwardly curving, curve d-threshold and curve e-
hormetic. Data points indicate the lower limit of doses where significant risks have
been demonstrated in human populations (10-50 mSv for acute exposure). [94]
The bystander effect is a phenomenon where signals are sent out by radiation dam-
aged cells to adjacent cells, causing oncogenic damage to these cells. This effect pre-
dominates at low doses and saturates at higher doses [105]. The cells may have an
adaptive response, where by DNA repair mechanisms are up-regulated from a small
radiation dose, reducing the radio sensitivity to larger subsequent doses [106, 107].
The bystander effect is being studied in pre-clinical trials, with responses measured
for exposures as low as a single proton or He ion [108]. Its impact on current radi-
ation therapy is yet to be investigated. These effects cause an increased risk, more
representative of the downward curve b.
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Curve c is representative of a quadratic relationship which increases with dose
and has been shown to provide a good description of acute dose-effect relations for
radiation-induced leukemia [84]. Curve d demonstrates a threshold response, below
which the risk is zero. This response is supported by the lack of radiation-induced
sarcomas observed at low doses [109]. Curve e represents a hormetic response, which
reduced the background incidence of some deleterious endpoint.
2.4.3.1 International Commission on Radiological Protection Report 103
The International Commission on Radiological Protection (ICRP) provides a set of
guidelines and recommendations for radiation protection. The report lists dose lim-
its for radiation workers and the general public based on risk of excess fatal cancer
following exposure to low-level ionisting radiation [62]. The risk is determined by
multiplying the effective dose following exposure by a nominal probability coefficient.
The probability coefficients are primarily derived from Atomic-bomb survivor data by
applying age and gender averaging for an occupational worker.








where wT is the tissue weighting factor for tissue T and the sum of all tissue
weighting factors = 1. The tissue weighting factor depends on the relative radio
sensitivity of each organ. A summary of tissue weighting factors from Report 103 is
given in table 2.5.
∑
R wRDT,R is the equivalent dose in Sieverts (J.Kg
−1), denoted HT . The equiva-
lent dose takes the dose received by the organ and scales it by the radiation weighting








Bladder, Oesophagus, Liver, Thyroid 0.04 0.16
Bone surface, Brain, Salivary glands, Skin 0.01 0.04
Total 1.00
* Remainder tissues: Adrenals, Extrathoracic (ET) region, Gall bladder, Heart,
Kidneys, Lymphatic nodes, Muscle, Oral mucosa, Pancreas, Prostate, Small intestine,
Spleen, Thymus, Uterus/cervix
Table 2.5: ICRP 103 Tissue Weighting Factors
factor wR which depends on the relative quality of the radiation which delivered the
dose. For photons, electrons and muons, the Linear Energy Transfer is less than 10
keV.µm−1 and has a wR value of 1. This value is higher than 1 for higher LET particles
such as protons, ions and neutrons.
The Report 103 models were developed for radiation protection purposes in the
low-dose range (less than 2.5 Sv). During radiotherapy, organs close to the target
volume may receive moderate to high doses, which is not included in the risk estimates.
Additionally, cancer patients receiving radiotherapy are generally older so the age
averaged coefficient may not be appropriate.
2.4.3.2 Biological effects of ionising radiation report VII phase 2
The BEIR Report VII published in 2006, applies a linear-no-threshold model to asses
the ERR and EAR following exposure to low-dose, low LET radiations [104]. Unlike
the ICRP models, age, sex and irradiated tissue effect the risk calculations, rather
than taking an average of epidemiological data. The EAR and ERR are combined to
estimate the likelihood of a radiation induced cancer over the lifetime of the individual,
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so called the Lifetime Attributable Risk (LAR) and is defined as:







Where e and a are age at exposure and attained age, respectively. M(D,e,a) is the
logarithmic weighted average of ERR and EAR, and S(a)
S(e)
is the probability of surviving
from ages e to a.
To use risk analysis a clinical site is usually chosen for parameter selection. Anthro-
pomorphic dosimetry phantom or Monte Carlo simulations provide more detailed dose
for a given organ site. Because measurements in this thesis are restricted to central
and peripheral doses in a cylindrical phantom and dose profile measurements not in
organ specific sites, we have not calculated risk from dose measurement in this thesis.
Chapter 3
Evaluating CTDI, CBDI, IAEA
and TG111 Methodologies for
Clinical CBCT Settings
Three alternative methodologies to the CTDI, the CBDI, IAEA and TG111 were
evaluated on two commercial CBCT imaging systems, the Varian OBIr on the C-
Series platform and XIr on Truebeam. Each methodology was compared for the main
clinical settings on each system for head and neck, thorax and pelvis imaging.
3.1 Measuring the CTDI and CBDI
3.1.1 Phantom Design and Materials
A standard 32cm diameter body phantom and 16cm diameter head phantom were
used for CTDI and CBDI measurements, as shown in figure 3.1. The phantom is
constructed from Poly methyl Methacrylate (PMMA) with a density of 1.18 g
cm3
and
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Both phantoms have insert spaces for a 100mm pencil ionisation chamber at the
centre and at the four peripheral locations shown in figure 3.1. The phantom was
placed on the couch and held in place with tape and low density foam blocks during
measurements. The phantom was aligned to the centre markings on the phantom
using the lasers in the room.
Figure 3.1: PMMA 32cm CTDI body phantom with the pencil chamber in the central
position. For head protocols the 16cm inner phantom was used.
3.1.1.1 UNFORS RaySafeTM Xi Measurement Device
CTDI and CBDI measurements were taken using the UNFORS Xi detector system
from RaySafeTM . The system includes a base unit which connects to several detectors
including a CT detector and HVL measurement tool for kV energies shown in figure
3.2. The base unit supports both RS-232/USB and blue tooth for data communication.
The pencil ionisation chamber for CT measurement has a sensitive length of 100mm.
The ionisation chamber and electronics are combined, with temperature and pressure
3.1. Measuring the CTDI and CBDI 45
Figure 3.2: The RaySafe Xi system used for CTDI and CBDI measurements. The CT
pencil chamber detector has a sensitive length of 100mm. The HVL tool measures
beam quality for kV energies. Both connect to the base unit which gives a readout
with temperature and pressure corrections applied. Source: www.raysafe.com
measured by the device and the dose adjusted automatically. The temperature is mea-
sured inside the chamber sensitive length ensuring precise temperature measurements
in a CTDI phantom or free in air. The detector has a range of 10 µGy to 9999 Gy
with an uncertainty of ±5%. Its energy dependance is < 5% with an axial and radial
uniformity of ±2% and ±3% respectively [110].
Measured data can be viewed on the base units back lit alphanumerical display
and is stored in XML or CSV format. With the Xi view program installed, data can
be transferred to a computer directly into a Microsoft ExcelTM document.
3.1.2 OBI and XI systems
Both Varianr kilovoltage CBCT imaging systems (OBI and XI) are mounted on the
LINAC gantry orthogonal to the treatment beam. Both systems consist of a kV X-ray
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tube and a flat panel detector 180 degrees to the tube. Each system can acquire 2D kV
and 3D CBCT images by acquiring projections as the source and detector are rotated
either 200 or 360 degrees. The parameters for each clinical mode for the 2 scanners













X-ray Voltage (kVp) 100 100 100 125 110
X-ray Current (mAs) 20 10 80 80 20
X-ray Milliseconds
(ms)
20 20 25 13 20
Gantry Rotation
(deg)
200 200 200 360 360
Number of Projec-
tions
360 360 360 665 665
Exposure (mAs) 145 72 720 680 262
CTDIw (mGy/100
mAs)
2.7 2.7 2.7 2.6 1.8
Dose CTDIw (mGy) 3.9 2.0 19.4 17.7 4.7
Fan Type Full Fan Full Fan Full Fan Half Fan Half Fan
Bow-tie Filter Full Full Full Half Half
Table 3.1: Modes and parameters for the OBI CBCT imaging system. [49]
Head Pelvis Thorax
X-ray Voltage (kVp) 100 125 125
X-ray Current (mAs) 20 80 20
X-ray Milliseconds (ms) 20 20 20
Gantry Rotation (deg) 200 360 360
Number of Projections 660 660 660
Exposure (mAs) 147 1056 264
CTDIw (mGy/100 mAs) 1.94 1.32 1.32
Dose CTDIw (mGy) 2.85 13.94 3.48
Fan Type Full Fan Half Fan Half Fan
Bow-tie Filter Full Half Half
Table 3.2: Modes and parameters for the Truebeam XI CBCT imaging system. [48]
The beam width is modified with independently adjustable X and Y lead blade
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collimators. The field size at isocentre can be varied from 2.0 mm x 2.0 mm to 50.0
cm x 50.0 cm for both the XI and OBI systems. The X1,Y1 collimators have a range
of -25.0 cm to +3.5 cm and the X2, Y2 from -3.5 cm to +25 cm. In the XI system, a
titanium beam hardening foil filter further hardens the X-ray spectrum to reduce low
energy photons.
The axial plane is further attenuated via a bow-tie filter. It shapes and filters the
beam to reduce patient skin dose, X-ray scatter and compensates for the curvature of
the patient body. The filters are constructed from aluminum and vary in thickness
from 2mm to 28mm. For head imaging a full bow-tie filter is used to provide symmetric
field scans while for body scans such as pelvis and thorax the half-fan is used with
an asymmetric field. The bow-tie filter is in-built into the XI system and will insert
the appropriate filter for the chosen scan, while the filter is applied to the kV unit
manually for the OBI system so care must be taken to ensure the appropriate filter is
in place when scanning.
3.1.3 Determination of CTDI and CBDI
Dose was measured by the pencil chamber for a CBCT scan in each position within
the phantom. This dose value represents the cumulative dose across the 100mm length
and multiplying by the chamber length yields the dose length integral (DLI).




where Dmeasured is the integral dose collected in scanning length Lc = 100mm.
This value was determined for each position within the phantom. To obtain the
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where coll is the collimation width at isocentre and D(z) the dose profile.
To obtain the CBDI, the DLI was divided by the 100mm chamber length Lc fol-





Hence, the CBDI values for the protocol scans are given simply by the dose mea-
sured in the chamber since scan length = chamber length.
CBDI[mGy] = Dmeasured (3.4)
The weighted CTDIw was determined by applying the weighted CTDI formalism














Where E is the scan mAs. The mAs for each of the protocols was taken from the
Varianr imaging manuals.
3.1.3.1 Fan-Beam CT Measurements
Initial CTDI measurements were taken on a Siemens SOMATOM CT scanner for
several scan settings to compare measured CTDI values with scanner predicted values
for narrow beam axial scanning. It was noted that the scanner value was quoted as a
CTDIvol, however since the scans were acquired with a single rotation in axial mode
there was no pitch to divide by, hence CTDIw was taken as CTDIvol. The phantom
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was fixed to the couch with tape and held in position with low density foam blocks as
shown in figure 3.1. The scan parameters are given in table 3.3.
Protocol kV mAs slice width
(mm)
Prostate Seeds 1 120 180 5
Prostate Seeds 2 120 180 10
Extreme Clinical Limits 140 300 5
Head and Neck 120 220 5
Table 3.3: Scan parameters for CTDI calculations on SOMATOM CT
An average of five measurements was taken for the five positions within the CTDI
phantom for CTDIw calculations. The CTDIw and
nCTDIw were then calculated for




Prostate Seeds 5mm slice 12.11 ± 0.03 6.73 ± 0.02
Prostate Seeds 10mm slice 12.75 ± 0.04 7.08 ± 0.02
Head and Neck-body phantom 14.98 ± 0.03 6.81 ± 0.01
Head and Neck 29.84 ± 0.03 13.56 ± 0.01
Extreme Clinical Limits 29.88 ± 0.05 9.96 ± 0.02
Table 3.4: Calculated CTDIw and
nCTDIw in mGy for clinical protocols on a SO-
MATOM CT scanner. The normalized values are per 100mAs. Quoted uncertainties
represent 1 standard deviation.
The Extreme Clinical Limits and Head and Neck (measured in the 16 cm diameter
phantom) protocols gave the highest values of 29.88±0.05 mGy and 29.84±0.03 mGy
respectively, more than double the other measured protocols which varied between
12.11± 0.03 mGy and 14.98± 0.03 mGy. The higher dose from the Extreme Clinical
Limits and Head and Neck (measured in head phantom) protocols are attributed to a
higher mAs and less attenuation from to the smaller phantom in the case of the Head
and Neck protocol scan.
The nCTDIw values varied by 6.84 mGy. The Head and Neck protocol in the 16
cm phantom gave the highest value of 13.56± 0.01 mGy.
3.1. Measuring the CTDI and CBDI 50
A comparison between the measured CTDIw with the CTDIvol values from by the
CT scanner for each mode are presented in figure 3.3.
Figure 3.3: Measured CTDIw and CTDIvol values taken from the scanner for Prostate
Seeds with 5mm and 10mm slice width, Head and Neck and Extreme Clinical Limits
modes. The measurements for the Head and Neck protocol were taken in the 32cm
diameter CTDI phantom. The error bars represent 2 standard deviations or 95% CI.
The quoted scanner values were higher than the measured CTDI values across all
clinical settings by an average of 2.65 mGy. The highest variation was 5.01 mGy for
the Extreme Clinical Limits scan due to its higher mAs.
3.1.3.2 CBCT Measurements
The CTDI, CTDIw and
nCTDIw were determined on two Varian
r imaging systems,
the On-Board Imagerr and the Truebeam X-Ray Imaging System (XI)r. The CTDI
body phantom was used for pelvis and thorax scans, and the CTDI-head phantom for
all head protocols. These values were compared to determine the difference in dose
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between the two imaging systems. The kV, mAs and collimation widths are given in
tables 3.5 and 3.6.
When the imaging system begins, there is a small delay between the beam starting
and the gantry rotating, so the side of the phantom where the tube begins its rotation
receives a higher dose. To reduce the effect of gantry start/stop position on the
measurement, two scans were acquired for each chamber position in the phantom, one
with the gantry rotated clockwise and the other counter-clockwise. An average of
these values was then taken to determine CTDI, CTDIw and
nCTDIw.






Pelvis 125 680 206 303
Thorax 110 262 206 303
Standard Head 100 145 184 272
High Dose Head 100 720 184 272
Low Dose Head 100 72 184 272
Table 3.5: Scan parameters for CBCT protocols on the OBI system






Pelvis 125 1056 214 281
Pelvis Obese 140 - - 214 281
Thorax 125 264 214 281
Head 100 147 214 280
Table 3.6: Scan parameters for CBCT protocols on the XI system. The mAs for the
Pelvis Obese scan couldn’t be determined as the parameters were not available from
the Truebeamr imaging manual.
The calculated CTDIw and normalised
nCTDIw for OBI and XI are presented in
table 3.7.
The XI Pelvis Obese protocol measured the highest with 20.743±1.475 mGy. The
Pelvis protocols gave similar values on both systems, with the XI system measuring




Pelvis OBI 9.408 ± 0.029 1.384 ± 0.004
Pelvis XI 9.646 ± 0.134 0.913 ± 0.056
Pelvis Obese XI 20.743 ± 1.475 - -
Thorax OBI 2.536 ± 0.004 0.968 ± 0.002
Thorax XI 2.302 ± 0.014 0.879 ± 0.006
Std Head OBI 2.236 ± 0.003 1.542 ± 0.002
Low Head OBI 1.184 ± 0.005 1.644 ± 0.007
High Head OBI 11.349 ± 0.046 1.576 ± 0.006
Head XI 1.648 ± 0.002 1.121 ± 0.005
Table 3.7: Calculated CTDIw and
nCTDIw values in mGy for clinical CBCT protocols
on the OBI and XI systems. Uncertainties represent 1 standard deviation.
slightly higher with 9.646±0.134 mGy compared with 9.408±0.029 mGy on the OBI.
For the Thorax protocols the OBI system gave a slightly higher value of 2.536± 0.004
mGy compared with the XI value of 2.302 ± 0.014 mGy. The OBI system has three
Head Protocols available with varying mAs, given in table 3.5. The differences in mAs
were reflected in the measured dose values which varied between 11.349± 0.046 mGy
for High Dose Head down to 1.184 ± 0.005 mGy for the Low Dose Head protocol.
Comparing the mid range Standard Dose Head OBI protocol with the Head protocol
of the XI system, the OBI protocol recorded the higher value of 2.236 ± 0.003 mGy
compared with 1.648± 0.002 mGy for the XI system.
The normalized nCTDIw values were more consistent across all protocols, varying
between 0.879±0.006 mGy.100mAs−1 for XI Thorax to 1.644±0.007mGy.100mAs−1
for Low Dose Head OBI. Generally the OBI protocols gave higher nCTDIw values with
an average of 1.298 mGy.100mAs−1 across the Pelvis, Thorax and Standard Head
protocols compared with 0.971 mGy.100mAs−1 for the corresponding XI protocols.
The mAs for the Pelvis Obese protocol was not given by the Varian Imaging manual
so its normalized value was not determined. The higher normalised values for the
OBI system reflect the higher contribution of low energy photons in the spectrum to
delivered dose, given the measurement conditions were identical and the kVp between
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the two imaging systems are equivalent for pelvis and head protocols, and 15 kV
different for thorax.
The CBDIw and
nCBDIw were calculated using equations 3.5 and 3.6 and are




Pelvis OBI 19.381 ± 0.029 2.850 ± 0.004
Pelvis XI 20.642 ± 0.134 1.955 ± 0.056
Pelvis Obese XI 44.390 ± 1.475 - -
Thorax OBI 5.225 ± 0.004 1.994 ± 0.002
Thorax XI 4.927 ± 0.014 1.866 ± 0.006
Std Head OBI 4.605 ± 0.003 3.176 ± 0.002
Low Head OBI 2.439 ± 0.005 3.388 ± 0.007
High Head OBI 23.380 ± 0.005 3.247 ± 0.006
Head XI 3.527 ± 0.002 2.399 ± 0.005
Table 3.8: Calculated CBDIw and
nCBDIw values in mGy for clinical CBCT protocols
on the OBI and XI systems.
The trends described above for CTDIw and
nCTDIw also follow for CBDI. However
the CBDI values are more than twice the CTDI, with an increase of 106 % for OBI
and 114 % for XI protocols.
The significant difference between CTDI and CBDI is attributed to the breakdown
of the CTDI principle of measuring the integral dose profile, since for CBCT the
primary beam width exceeds the integration length of the ionization chamber. By
dividing the DLI by the chamber sensitive length rather than beam width as shown in
equation 3.3, the values are up scaled and hence give a more realistic dose estimate.
For clinical practicality the CBDI was performed with only the CTDI phantom and
no additional scatter material, as described in the original procedure [13]. The lack of
scatter will produce a small decrease in the measured dose, and should be taken into
consideration when interpreting these results.
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3.2 IAEA Report 5 Protocol
The biggest limitation of the CTDI method is its underestimation of patient dose due
to scatter dose beyond the 100 mm detector sensitive volume not being included in the
measurement. It has been shown that this underestimation is relatively constant for
beam widths up to 40 mm at isocentre, but decreases for beam widths greater than
this as shown in figure 2.13 [72]. The IAEA recommends a new protocol which takes
advantage of the constant efficiency of CTDI for beam widths < 40 mm and translates
it to wide beam scanning, as described in section 2.3.3.2.
The protocol stipulates CTDI be determined for a reference beam width not ex-
ceeding 40 mm. This value is then scaled by the ratio of the free in-air CTDI values
for the same reference beam, and the width of the beam for which the CTDI is to be
determined:






Reference scans were taken for the same kV, mAs and axial collimation as the
protocol scans, but the z-axis collimation was set to the 20 mm, recommended by the
IAEA [11] for the reference width, as it’s well within the linear efficiency range for
CTDI.
The existing 100 mm ionisation chamber was used for the free in-air measurements.
For the protocol widths, the IAEA specifies a minimum scan length of the beam width
+ 40 mm, or 20 mm either side of the beam. For half-fan protocols the beam width was
206 mm for OBI and 214 mm for the XI system, with a minimum scan requirement of
246 mm and 254 mm respectively. Given the chamber length of 100 mm, the chamber
was stepped through the beam in 100 mm increments for a total scan length of 300
mm, as shown below:
The dose for each position, multiplied by the chamber length Lc is then summed
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Figure 3.4: Diagram demonstrating the measurement of CTDI free in-air stepping the
100 mm chamber in increments equal to the chamber length. Source: [11]







The free in-air measurement assumes no scatter contribution to the dose measure-
ments. Hence, the ionisation chamber was held away from the couch by a retort stand
and support rod. The distance from the couch was made to be greater than half the
beam width, as specified by the IAEA. The set up is shown in figure 3.5.
Free in-air measurements were taken for reference and protocol width beams for
the major clinical protocols on the OBI and IX imaging systems. The CTDIIAEA
was then determined from equation (3.7) and the reference width CTDI values. The
weighted CTDIIAEA was calculated from equation (3.5). The peripheral values were
scaled by the same in-air CTDI since there is no phantom attenuation.
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Figure 3.5: 100 mm chamber extended from couch by support structure for free in-air
measurements. The distance of the chamber from the couch is greater than half the
beam width
3.2.1 IAEA Measurements
The CTDIin−air values and their ratios for the OBI and XI systems are presented in
table 3.9 and the weighted CTDIIAEA and normalised
nCBDIIAEA for the OBI and
XI imaging protocols in table 3.10. The Thorax mode on the OBI system could not
be evaluated for the IAEA protocol due to signal from the reference width scan in the
PMMA phantom being too small to be detected by the UNFORS detector.
The average ratio for the OBI system was 16% higher than the XI system. The
difference between OBI and XI is due to the XI system having additional beam fil-
tration from the titanium filter which hardens the spectra, removing the lower energy
photons. Thus the photon fluence is larger in the OBI beam and more energy is de-
posited within the pencil chamber. The difference is further emphasized by the long




Pelvis OBI 57.875 74.041 1.279
Pelvis XI 67.100 69.127 1.030
Pelvis Obese XI 139.150 143.511 1.031
Thorax OBI 17.005 21.058 1.238
Thorax XI 16.415 16.935 1.032
Std Head OBI 7.890 9.489 1.203
Low Head OBI 4.081 5.024 1.231
High Head OBI 38.730 47.332 1.222
Head XI 5.105 5.291 1.036
Table 3.9: Calculated CTDIrefin−air and CTDI
protocol
in−air values in mGy for clinical CBCT
protocols and the ratio of the two for the OBI and XI systems.
scan lengths taken to record the full dose profiles of the CBCT scans.
Protocol IAEAw
nIAEAw
Pelvis OBI 18.343 ± 0.002 2.698 ± 0.004
Pelvis XI 14.771 ± 0.001 1.399 ± 0.000
Pelvis Obese XI 32.295 ± 0.017 - -
Thorax XI 4.441 ± 0.001 1.682 ± 0.000
Std Head OBI 3.747 ± 0.018 2.584 ± 0.002
Low Head OBI 1.726 ± 0.007 2.397 ± 0.007
High Head OBI 15.316 ± 0.002 2.127 ± 0.006
Head XI 3.741 ± 0.033 2.545 ± 0.111
Table 3.10: Calculated IAEAw and
nIAEAw values in mGy and mGy.100mAs
−1
for clinical CBCT protocols on the OBI and XI systems. Uncertainties represent 1
standard deviation.
Overall the Pelvis Obese mode delivered the highest value of 32.295 ± 0.017 mGy
due to its high mAs. The Low Dose Head mode recorded the lowest value of 1.726 ±
0.007 mGy, with 72 mAs per scan. The High Dose Head mode delivered a much higher
dose of 15.316 ± 0.002 mGy compared with the other Head modes, but delivered the
lowest dose per mAs of all the head protocols measured.
The IAEAw values were 3.572 mGy higher for OBI pelvis compared with XI pelvis.
OBI standard head mode and XI head mode were within 0.01 mGy. The higher
OBI values for pelvis modes were attributed to lower CTDI in−airref values and higher
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CTDIprotocolin−air values compared with the XI system as shown in table 3.9. A possible
cause is higher deflection of low energy photons in the OBI beam from collimators
falling outside the reference scan width.
The nIAEAw values were also higher for the OBI system. The Pelvis modes varied
by 1.299 mGy.100mAs−1 while for Head the variation was 0.039 mGy.100mAs−1. This
is due to the increased fluence of the OBI system from low energy photons as described
earlier.
3.3 AAPM TG111 Methodology
The TG111 report describes a new method for quantifying dose for any form of com-
puted tomography imaging. Unlike the methods described above, the dose about the
center of the scan length z = 0 is determined by a point dose measurement.
For CBCT, where there is no table translation and the image is acquired in a single
rotation of the x-ray tube, the methodology is simplified to measuring the central dose
d(z=0).
3.3.1 Phantom Design and Materials
3.3.1.1 TG111 Phantom design and Construction
The TG111 protocol allows flexibility in phantom material, radial dimensions and even
shape of the phantom. It also does not specify to which medium the dose values are
reported. The only requirement is that the phantom be of sufficient length to achieve
scatter equilibrium and be of uniform composition.
To fulfill the scatter requirements of the TG111 protocol, a new phantom was
manufactured at the University of Wollongong and is shown in figure 3.6.
The cylindrical PMMA phantom was constructed to match the 32cm diameter of
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(a)
(b)
Figure 3.6: TG111 phantom constructed in-house at the University of Wollongong. (a)
The length was made to be 45cm to reach scatter equilibrium in the central position.
(b) The cylindrical shape and diameter of 32cm is the same as the CTDI phantom.
There are 5 plugs within the phantom for CTDIw measurements.
the body CTDI phantom. 5 holes were drilled into the phantom for CTDIw style
measurements, one in the centre and 4 on the periphery equally spaced.
The phantom was constructed from 10 cylindrical slices 4.7cm in thickness. Each
slice was milled and the holes drilled independently, then glued together using custom
made metal plugs to align all the slices as shown in figure 3.7.
3.3.1.2 Chamber Plug Design
The plug housing the ionisation chamber was constructed to conform to the chamber
geometry to eliminate air gaps around the sensitive volume and minimise air gaps
around the cable. The plug contains three sections. The rear section has a bore hole
through which the cable feeds out of the phantom, the middle section which houses
the chamber and the end section which is solid. The other 4 holes contain solid rods
that can be taken out and rotated with the chamber plug.
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(a) (b) (c)
Figure 3.7: (a) Each slice was individually cut and milled to house plus for ionisation
chamber measurements. (b) One of the 4 PMMA plugs that fill the unused chamber
holes. (c) Single phantom slice side on. The width of each slice was 4.7 cm.
(a) (b)
Figure 3.8: Plug housing 0.6cc farmer ionisation chamber in the TG111 phantom. The
plug contains 3 sections, one to run the cable out of the phantom, a middle section
milled to conform to the chamber and a solid front section to fill the plug housing.
3.3.1.3 Charge Collection
The chamber used for the TG111 measurements was a 0.6cc NE 2571 Farmer ionisation
chamber. The sensitive air volume has a length of 24mm and radius 3.2mm. It is
enclosed by a graphite thimble of thickness 0.065g.cm−2. The chamber operates at a
bias voltage of 300V between the stem and chamber wall.
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The chamber was connected to a PTW UNIDOSE Webline Type T10023 electrom-
eter. The ionisation chamber and electrometer combination are calibrated in the kV
energy range against the Australian primary standard at the Australian Radiation
Protection and Nuclear Safety Agency (ARPANSA).
Following the TG111 protocol for stationary table translation, a single CBCT was
acquired for each clinical protocol on the OBI and XI imaging systems. Only half-fan
protocols were tested as no head phantom was constructed. Two measurements per-
formed at different rotation direction were taken for each position within the phantom
and averaged to eliminate gantry start-stop effects.
The weighted value was determined in the same way as for the CBDI and IAEA
protocols using equation 3.5.
3.3.1.4 Conversion of Charge Readings to Dose
The reading from the ionisation chamber is given as a charge value in nano-coulombs.
The conversion from charge to dose was performed in accordance with the AAPM









where q is the total charge collected by the ionisation chamber (C) (with the appro-
priate temperature and pressure corrections) and NK is the air KERMA calibration
factor (mGy.nC−1) for the ionisation chamber. NK is dependent on beam quality
measured by HVL. NK was interpolated from the ARPANSA calibration certificate
for the appropriate HVL of the imaging beams, however NK did not vary significantly






term is the ratio of the spectrally averaged
mass-energy absorption coefficients of the phantom material to air. Unless otherwise
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= 1. This approach is consistent with IAEA dose formalisms in diagnostic
radiology [112].





(T [◦C] + 273.2)
(Tref [◦C] + 273.2)
(3.10)
The HVL of the imaging beams was measured using the UNFORS HVL mea-
surement tool shown in figure 3.2. The Unfors greatly simplified HVL determination
compared with a direct measurement, which requires several measurements with in-
creasing amounts of lead attenuator [111] .The accuracy of the device was verified by
measuring HVL for several beam qualities on an orthovoltage unit with known HVL
values previously determined following the TG61 protocol [111].
(a) (b)
Figure 3.9: (a) Determination of the HVL on the orthovoltage unit using the UNFORS
HVL tool. A 5cm diameter cone is attached at 30cm SSD. (b) Back scatter correction
measurements were taken with the 10 cm diameter cone on a low-scatter stand.
The set up is shown in figure 3.9 (a). The HVL was determined for 3 filters to
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cover a broad range of HVL’s corresponding to the expected HVL’s for CBCT beams.
3 measurements were taken for each filter and an average value determined.
The HVL tool had a trigger delay set to 2s to avoid measuring in the ’ramp up’
phase of beam delivery as shown in figure 3.10. 25MU was delivered in the measure-
ment.
Figure 3.10: kV tube output as a function of time for the ortho-voltage measurement.
By introducing a 2s trigger delay a uniform kV was obtained for the HVL measurement.
Measurements were also taken with the HVL tool elevated with a low-scatter stand
to evaluate back-scatter contributions as shown in figure 3.9 (b). Variation in HVL
due to residual scatter was in the order of 0.1mmAl so was assumed small enough not
to be included in error calculations.
The measured HVL’s from the UNFORS and the reference HVL values are shown
in table 3.11.




1 100 28 3.58 3.67
2 125 23 6.15 6.30
3 150 14 9.67 9.67
Table 3.11: Calibration HVL values for settings tested on the Ortho-Voltage unit. The
calibrated values were determined from machine QA following the TG61 protocol.
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After verifying the UNFORS HVL tool was in agreement with the known HVL
of the ortho-voltage beam, measurements were acquired for the OBI and XI systems.
The tool was placed at isocentre on the couch with the cross-hairs aligned with the
sensitive region of the detector as shown in 3.11.
Figure 3.11: Set-up for the measurement of HVL on the CBCT imaging systems. The
UNFORS HVL tool was placed on the treatment couch at isocentre and scanned under
CBCT clinical mode parameters in kV fluoroscopy mode. The detector was oriented
orthogonally to the cathode-anode direction.
Two measurements were taken for each set of clinical CBCT modes and the values
averaged. The scan was acquired in kV fluoroscopy mode.
3.3.2 Determining air KERMA Conversion Values
The ARPANSA air KERMA calibration factors were entered into MATLABr and a
curve fit to the data using the MATLAB curve fitting program as shown in figure 3.12.
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Figure 3.12: Curve fit of air KERMA per PC from ARPANSA calibration report.
Using the fit function air KERMA conversion factors were determined from the
measured HVL values and are listed in table 3.12.
Protocol HVL (mmAl) Correction Factor
NK (mGy.nC
−1)
OBI Thorax 5.20 41.629
OBI Pelvis 5.84 41.618
XI Pelvis 8.43 41.591
XI Pelvis Obese 8.94 41.565
XI Thorax 8.23 41.578
Table 3.12: HVL and corresponding air KERMA corrections for the farmer chamber.
The corrections were determined from the curve fit of the ARPANSA data 3.12.
3.3.3 TG111 Measurements
The weighted TG111 values are shown in table 3.13 for OBI and XI systems.
The highest TG111w measured was 48.529 mGy for XI Pelvis Obese mode and the
lowest value 5.540 mGy for Thorax XI mode. The XI measured 5% higher than OBI
for Pelvis mode while for Thorax the OBI system was higher by 20%. The normalised
nTG111w was higher for Pelvis and Thorax modes on the OBI system by 32% and
21% respectively. The reasons behind the variations for Thorax modes and normalised
values are due to the larger component of low energy photons in the OBI system. For
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Protocol TG111w
nTG111w
Pelvis OBI 21.199 ± 0.014 3.112 ± 0.002
Pelvis XI 22.420 ± 0.001 2.123 ± 0.000
Pelvis Obese XI 48.529 ± 0.012 - -
Thorax OBI 6.963 ± 0.001 2.658 ± 0.000
Thorax XI 5.540 ± 0.000 2.098 ± 0.000
Table 3.13: Calculated TG111w and
nTG111w values in mGy and mGy.100mAs
−1
for clinical CBCT protocols on the OBI and XI systems. Uncertainties represent 1
standard deviation.
the purpose of this work, uncertainties were calculated from the collected data and do
not included uncertainties in the calibration of the chamber, electrometer etc. Further
information regarding the inclusion of these uncertainties can be found in the literature
[113].
3.4 Comparison of Methodologies
A comparison of CTDI, CBDI, IAEA and TG111 for Pelvis and Thorax modes on
OBI and XI systems are illustrated in figure 3.13. A summary of the four protocols
for each imaging mode are shown in table 3.14.
Protocol CTDIw CBDIw IAEAw TG111w
Pelvis OBI 9.408 ± 0.029 19.381 ± 0.029 18.343 ± 0.002 21.199 ± 0.014
Pelvis XI 9.646 ± 0.134 20.642 ± 0.134 14.771 ± 0.001 22.420 ± 0.001
Pelvis Obese XI 20.743 ± 1.475 44.390 ± 1.475 32.295 ± 0.017 48.529 ± 0.012
Thorax OBI 2.536 ± 0.004 5.225 ± 0.004 - - 6.963 ± 0.001
Thorax XI 2.302 ± 0.014 4.927 ± 0.014 4.441 ± 0.001 5.540 ± 0.000
Std Head OBI 2.236 ± 0.003 4.605 ± 0.003 3.747 ± 0.018 - -
Low Head OBI 1.184 ± 0.005 2.439 ± 0.005 1.726 ± 0.007 - -
High Head OBI 11.349 ± 0.005 23.380 ± 0.005 15.316 ± 0.002 - -
Head XI 1.648 ± 0.002 3.527 ± 0.002 3.746 ± 0.033 - -
Table 3.14: Calculated CTDI, CBDI, IAEAw and TG111w values in mGy for clinical
CBCT protocols on the OBI system. Uncertainties represent 1 standard deviation.
The TG111 methodology measured the highest dose for all half-fan CBCT modes
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Figure 3.13: A comparison of CTDI, CBDI, IAEA and TG111 weighted values on the
four full-fan CBCT modes studied. Error bars represent 1 standard deviation.
due to full scatter being achieved in the centre of the TG111 phantom. The CBDI,
which up scales CTDI to better approximate CBCT dose gave the second highest dose
for half-fan modes. For full-fan scans where TG111 was not evaluated, the CBDI gave
the highest dose across all scan modes except for the XI head protocol. The slightly
lower CBDI values compared with TG111 is due to CTDI phantom not having sufficient
length to achieve scatter equilibrium. As previously described in 3.1.3.2, this would
not have been the case if additional scatter material was included.
The IAEA method gave the third highest dose across the half-fan modes and the the
second highest reading for full-fan modes behind the CBDI. The lower doses from the
IAEA method are attributed to the lack of scatter dose contributing to the in-phantom
measurements compared with the TG111 and CBDI methods. The larger difference
between IAEA with the CBDI and TG111 methods on the XI system was due to
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variations in the free-air beams. The lower energy photons on the OBI system leads
to a lower reference width dose in air compared with XI, but a larger dose for protocol
beam width. Thus, the ratio of in-air CTDI values is greater for the OBI system which
gives a higher overall value for IAEA. The CTDI method gave the lowest dose for all
CBCT scans due to the CTDI phantom lacking the sufficient length to achieve full
scatter and the 100mm sensitive length of the ionisation chamber being inadequate to
capture the full beam width leading to an underestimation of the integral dose.
The TG111 values closely match those of Hu et. al. [8], who quotes a weighted
pelvis TG111 value of 22.70 mGy compared with an average of 21.80 mGy measured
across the two CBCT imaging systems in this study. Conversely, CTDI100 values from
this study were lower, with a pelvis value of 18.06 mGy compared with an average
value of 9.53 mGy in this study. For head protocols, Hu measured 5.53 mGy compared
with an average of 1.94 mGy. IAEA values were also slightly lower for our study. Hu
measured IAEA values for pelvis and head of 4.89 mGy and 15.86 mGy, compared with
average values of 16.60 mGy and 3.75 mGy, respectively. Interestingly, the mAs and
kV settings were similar between the two studies, particularly for the OBI system, with
the collimation width being wider for the protocols in this study compared with Hu
et. al. These results may suggest a variation in beam quality between the two studies,
particularly with the XI imaging system, resulting in a greater scatter contribution
to measurements in Hu’s work, particularly when considering protocols with larger
chamber lengths (CTDI, IAEA).
The TG111 methodology delivers the highest CBCT dose due to the full scatter of
the 45 cm TG111 phantom. The CBDI methodology provides a good estimate to the
TG111 methodology using the existing CTDI phantom and pencil chamber and may
offer a more clinically applicable determination for CBCT dose.
It’s worth noting that these values are also higher than the quoted CTDIw values
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given by the OBI and XI systems as shown in figures 3.1 and 3.2 respectively. These
quoted values are evaluated for a reference beam width, similar to the process described
in the IAEA approach. However, the reference beam width is determined by measuring
the FWHM of the reference beam in-air rather that using the specified collimator
width. For this reference width, the full dose profile can be captured with the Pencil
chamber and hence gives an accurate quantitative comparison of dose for different
scanner settings. However it has been demonstrated that these values do not reflect
the dose from the corresponding clinical CBCT protocols.
Chapter 4
Beam Profile Measurements and
the Dosimetric Impact of Increased
Beam Width
4.1 Variation of Central Dose with Increasing Scan
Length
To investigate the limitations of the current methodology for wide beam scanning,
the four protocols were tested for increasing CBCT beam width in the z-axis. The
procedure was carried out as previously described using the Pelvis protocol on the
OBI system. The beam widths tested were 2, 5, 10, 15, 20.6, 25 and 40 cm. The
beam width for the clinical pelvis protocol was 20.6cm, so this was chosen instead of
20 cm. The distance between successive measurements was increased for the wider
beam widths as variation in dose became much smaller due to equilibrium dose being
approached.
Measurements were taken in the central and peripheral positions within the re-
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spective phantoms and used to calculate the weighted values for each scan width for
the CTDI, CBDI, IAEA and TG111 protocols.
4.1.1 Beam Width Measurements












2 14.338 2.545 14.338 5.838
5 15.142 7.100 15.142 11.790
10 14.246 14.246 16.262 15.904
15 12.144 18.217 18.545 18.387
20.6 9.430 19.427 18.343 20.064
25 7.933 19.833 18.538 21.122
40 5.047 20.187 18.260 22.445
Table 4.1: Comparison of weighted measurements for CTDI, CBDI, IAEA and TG111
protocols in mGy for the OBI Pelvis scan mode. A CTDI phantom was used for
CTDI, CBDI and IAEA measurements, while the TG111 phantom was used for TG111
measurements.
For beam widths less than 10 cm the CTDI recorded the highest dose, measuring
14.338 mGy and 15.142 mGy at 2 cm and 5 cm respectively. The IAEA and CTDI
values are equivalent for beam widths less than 60 mm. The CBDI and TG111 pro-
tocols recorded lower doses, with TG111 being slightly higher than CBDI. The CBDI
is lower as the dose is divided by the 10 cm chamber length, rather than collimation
width. For collimation widths below 10 cm the chamber is measuring the average of
the profile, which includes in-beam and out of beam and hence, it is not measuring
dose in the centre of the collimated beam width. This averaging is less pronounced in
TG111 as the Farmer chamber has a shorter sensitive length of 2.4 cm. However aver-
aging will still occur and a smaller chamber would be required to accurately determine
peak dose for a 2 cm beam width.
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Figure 4.1: Weighted dose measurements with increasing z-axis beam width for CTDI,
CBDI, IAEA and TG111 protocols. The OBI Pelvis scan mode was used for all
measurements.
The difference between CTDI and IAEA with CBCT and TG111 for narrow beam
widths can be attributed to the reported overestimation of the average dose in the
phantom by the CTDI protocol for narrow scan lengths [31], which counters the re-
ported underestimation of the CTDI, even for narrow beam widths [72]. At 10 cm
beam width, the CTDI and CBDI protocols both measured values of 14.246 mGy
which was the maximum value for CTDI across all beam widths. For beams widths of
between 10 cm and 15 cm, the CBDI will overestimate the dose due to scatter contri-
butions at the far ends of the 100 cm chamber, which do not reach the centre of the
volume (and hence not detected by the Farmer chamber in the TG111 measurement).
This is however offset by the lack of additional scatter in the CBDI measurements
compared with TG111. If the CBDI was performed with additional scatter material
this would not be the case, and the CBDI would measure higher than the TG111 for
these beam widths.
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As the beam width increased further the CBDI and TG111 continued to increase
before plateauing. The maximum values for TG111 and CBDI occurred at 40 cm
measuring 22.445 mGy and 20.187 mGy respectively. The CBDI plateaued from 20.6
cm beam width with measurements increasing by only 0.760 mGy beyond 20.6 cm. The
TG111 plateau occurred closer to 40 cm beam width. The higher dose measured by
TG111 and longer beam width required to reach equilibrium compared with CBDI is
attributed to the increased scatter from the longer TG111 phantom and is consistent
with other results in the literature [80]. As previously stated in 3.1.3.2, the CBDI
method used here does not include additional scatter material.
The IAEA reached a plateau at 15cm measuring 18.545 mGy. Beyond 15 cm beam
width the IAEA varied by only 0.285 mGy. At 40 cm beam width, a slight drop in the
IAEA was observed. This is likely due to a limit being reached where increase in beam
fluence with increased collimator width is less than the increase in collimator width
itself, the divisor in the IAEA calculation. The IAEA protocol does not take into
account increased phantom scatter for longer scan lengths, however underestimates
CTDI∞ by the same fraction for all beam widths [11, 30]. Hence, the IAEA remains
steady when beam width is increased.
Beyond 10 cm beam width the CTDI gradually decreased to 3.520 mGy at 40 cm.
The CTDI is an integral dose metric which approximates the dose in the center of a
scan by integrating the full dose profile and dividing by collimation width as described
in section 2.3.1. As the beam is attenuated by the phantom, the dose profile in the
central position is spread due to phantom scatter. As the beam width is increased
the underestimation becomes more pronounced as larger portions of the beam fall be-
yond the 100 mm sensitive length of the Pencil ionisation chamber. Additionally the
collimation width, which is the divisor in CTDI, continues to increase further com-
pounding the underestimation of CTDI. Hence, the CTDI decreases with increasing
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beam width rather than an increase as was observed for the other protocols.
4.2 Integral Dose
The integral dose was calculated from equation 4.1 and represents the total energy
absorbed in the phantom:
Etot = ρπR
2LDeq (4.1)
The TG111 calculated values at 40 cm beam width were used for equilibrium dose
Deq for their respective scan modes, where Deq is the radially averaged dose in the
axial plane using the same weighting methodology described by equation (2.2). The
collimation width for the respective scan modes were used for the scan length L and
the ρ value used was the PMMA density of 1.19 g.cm−3 from the NIST database [114].
R represents the radius of the phantom.
4.2.1 Integral Dose Measurements
The Equilibrium dose Deq and integral dose Etot for each scan mode are presented in
table 4.2.
Protocol Deq (mGy) Integral Dose
(mJ)
Thorax OBI 6.54 ± 0.07 128.89 ± 1.29
Thorax XI 5.59 ± 0.06 114.49 ± 1.15
Pelvis OBI 22.61 ± 0.23 445.69 ± 4.46
Pelvis XI 22.58 ± 0.23 462.41 ± 4.62
Pelvis Obese XI 48.82 ± 0.49 999.81 ± 10.00
Table 4.2: Deq (mGy) and Etot (mJ) for the Pelvis and Thorax modes on the OBI and
XI imaging systems. A 1 percent error was applied to for Deq measurements.
The Pelvis Obese XI mode delivered the highest Etot of 999.81 ± 10.00 mJ due
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to its higher mAs and kV producing an increased amount of scatter photons to the
chamber in addition to an increased number of primary photons. Both Pelvis modes
gave similar values, with XI delivering a slightly higher 462.41 ± 4.62 mJ compared
with 445.69 ± 4.46 mJ from OBI. The higher XI value is due to the 211 mm collimation
width of the XI being slightly longer than the 206 mm collimation width of the OBI
scan. The XI system delivers 1056 mAs compared with 680 mAs for the OBI system
however the beam is hardened in the XI system by an additional titanium filter. The
filter removes low energy photons from the spectrum and increases the effective beam
energy. The overall effect is a similar dose deposition between the two systems for the
Pelvis scan with Deq varying by 0.03 mGy.
The Thorax measurement was higher for OBI with 128.89 ± 1.29 mJ compared
with 114.49 ± 1.15 mJ from the XI. Both Thorax modes have a similar mAs, however
due to the additional filtration on the XI system the OBI beam contains more photons.
These low energy photons increase the scatter dose, particularly for wide beam widths
where Deq is measured.
4.2.2 Integral Dose for Increasing Beam Width
The Integral Dose for varying beam width for each mode is presented in table 4.3 and













2 42.96 43.22 93.44 12.51 10.70
10 216.35 216.08 467.21 62.57 53.50
15 324.53 324.12 700.81 93.85 80.25
20.6 445.69 445.12 700.81 128.89 110.21
25 540.88 540.19 1168.01 156.42 133.75
40 865.41 864.31 1868.82 250.27 214.00
Table 4.3: Etot in mJ for increasing beam width for OBI Pelvis, OBI Thorax, XI Pelvis,
XI Pelvis Obese and XI Thorax.
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Figure 4.2: Integral Dose with increasing beam width for Pelvis modes.
Figure 4.3: Integral Dose with increasing beam width for Thorax modes.
The expected linear relationship was observed for Integral Dose with increasing
scan width. The higher mAs scans corresponded to a more dramatic increase in the
integral dose with the Pelvis Obese XI mode increasing from 93.44 mJ to 1868.82 mJ
from 2 cm to 40 cm. Both Pelvis OBI and Pelvis XI protocols had similar increases
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of 42.96 mJ to 865.41 mJ and 43.22 mJ to 864.31 mJ respectively. The increase was
higher for Thorax OBI compared with Thorax XI protocol, increasing from 12.51 mJ
to 250.27 mJ compared with 10.70 mJ to 214.00 mJ due to the higher scatter dose
from low energy photons in the OBI scan.
The increase was greater than for dose in the central slice of the phantom as
shown in figure 4.1, particularly for wide beam widths when the Equilibrium Dose is
approached. This result identifies the necessity to limit the beam width for CBCT
imaging to what is necessary, particularly for higher mAs scans such as the Pelvis
Obese protocol.
4.3 CBCT Beam Profiles
Beam profile measurements were taken for the half-fan pelvis mode in the TG111
phantom for XI and OBI imaging systems. The Farmer chamber was placed in the
central position within the phantom and stepped through the beam by moving the plug
housing the chamber within the phantom by 2.5 cm intervals, the sensitive length of
the chamber. Temperature and pressure corrections were applied to the measurements
and converted to dose to air using NK values from the chamber calibration certificate.
Profile measurements were also taken using GafchromicTM XR-QA2 film which is
designed for diagnostic energies of 20kVp-200kVp with a dose range of 0.1cGy-20cGy.
The film consists of a 97 micron polyester layer, 20 micron adhesive layer, 25 micron
active layer and a 97 micron white polyester backing layer. The film is self developing
and can be handled in room light.
4.3.1 Ionisation Chamber Measurements
The chamber measurements of the OBI and XI Pelvis dose profiles are illustrated in
figure 4.4.
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Figure 4.4: Farmer chamber measurements converted to mGy of the beam profiles
along the z-axis for OBI and XI Pelvis modes in the centre of the TG111 phantom.
The average collimated field width is shown with blue vertical lines (206mm for OBI
and 214mm for XI). The asymmetry in the XI profile is due to the heel effect.
Both profiles extend beyond the collimation width due to scatter within the phan-
tom. The OBI and XI measuring 62% and 58% of the central value at 10 cm beam
width respectively. The central dose is 3.2 mGy higher for the XI compared with OBI
due to the harder spectrum produced by the titanium filter in the XI system. However
further from the central region the dose becomes similar for the two systems, with the
average dose at the 12 cm position varying by an average of 1.2 mGy between OBI
and XI. There is an asymmetry in the XI profile due to the X-ray target running along
the z-axis and producing a heel effect. The target runs along the axial plane in the
OBI system. Some volume averaging over the ionisation chamber sensitive length may
also occur in the penumbral region where the dose gradient is steepest.
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4.3.2 Film Measurements
4.3.2.1 Film Calibration
Due to the known energy dependance of film at low photon energies[28, 24, 25] the
film was calibrated for both the OBI and XI imaging systems since the XI spectrum
is hardened with additional filtration compared with OBI.
The film was scanned prior to, and 24 hours post irradiation on an Epson Expres-
sion 10000 XL flat bed scanner at 72 dpi resolution in 48 bit colour RGB mode. The
scanner was operated in reflection mode with all colour corrections switched off. Prior
to scanning the film, six runs of the scanner were taken to warm up the lamp. Three
‘dummy’ images were taken of each batch of calibration film and 3 ‘keep’ images.
The red channel of the scanner was used for image analysis as this encompasses the
wavelength component associated with the most change in film colour [115].
Three 2 cm by 3 cm film pieces were placed along the z-axis for each exposure, with
one at isocentre and 1 piece adjacent on either side. The film was calibrated against air
KERMA measured with a 0.6 cc Farmer Ionisation chamber with calibration traceable
to a primary standard. The film was exposed to doses from 0cGy-4cGy. Exposures
were taken in steps of 0.5cGy from 0cGy-3cGy and then a single 1cGy step from 3cGy
to 4cGy. To avoid any angular dependence in film response due to beam rotation,
the calibration exposures were taken in kV fluoroscopy mode with the kVp, mAs,
collimator and bow-tie filter parameters as per a pelvis kV CBCT acquisition.
Because the length of exposure in fluoroscopy mode is controlled by the user, in
order to determine the dose delivered to the film, a reference detector was used during
the Farmer chamber and film exposures. The detector was placed in the beam a fixed
distance away from isocentre. An average ratio between the two detectors was then
used to determine isocentre dose when the Farmer chamber was replaced with the
calibration film as shown in figure 4.7.
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The post exposure films were analysed using ImageJ. Regions of interest (ROI)
were selected for each film piece and an average pixel intensity measured. The ROI
was chosen to maximise the ROI area while avoiding areas close to the film edges. A
macro was used to replicate the ROI’s across the three scans.
The mean pixel intensity for the three film pieces at each exposure were compared
on both the OBI and XI systems. In the XI system, the X-Ray tube runs along the
z-axis along with the three film pieces and it has been previously shown that the
heel effect can influence dose in air for kV CBCT scans [116, 117]. The average pixel
intensities for the 3 pieces across the measured doses are shown in figures 4.5 for the
OBI and 4.6 for the XI systems.
Figure 4.5: Comparison of mean pixel intensity across the selected ROI on the cali-
bration film pieces along the z-axis for measured doses on the OBI system.
No significant variation in the dose across the three film pieces was observed for
any of the doses measured for both the OBI and XI systems. It was concluded the
distance across the three film pieces was too small to be influenced by the heel effect
and would not influence the calibration.
The net reflectance (net∆R) for each exposure was then calculated using the aver-
age pixel value from the 3 pieces of film for each exposure using the method described
4.3. CBCT Beam Profiles 81
Figure 4.6: Comparison of mean pixel intensity across the selected ROI on the cali-
bration film pieces along the z-axis for measured doses on the XI system.
by Tomic et. al. [118]. The first step is to calculate the change in reflectance:
∆Ri = Ribefore −Riafter =
1
216
[PV ibefore − PV iafter] (4.2)
where PV is the average pixel value from the selected ROI of film piece i analysed
using the red channel and reflectance is calculated as PV
216
. The error on reflectance






2 + (σ(PV iafter))
2 (4.3)
The average change in reflectance (∆̄R) for each exposure was then determined
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The process was repeated for three control pieces which received no dose and the
result subtracted to obtain the final reflectance change net∆R:
net∆R = ∆̄R− ¯∆Rcontrol (4.7)





The net∆R values with the corresponding doses were imported into MATLAB and
a curve fitted using the curve fitting application for both the OBI and XI systems.
The fit equation used by Giaddui et. al. [25] of the form y = ax
b−x was applied, where
a and b are coefficients and x and y represent net∆R and dose to film respectively.
This fit function has the benefit of linearity, is monotonically increasing and returns a
zero value for zero dose.
Previous studies with XR-QA film have suggested the response of the film in-air
compared with PMMA scatter conditions is within ±2%[29]. To verify the response
of the film did not vary between free air and in the PMMA phantom, two calibrations
for each condition were produced on the OBI and XI systems. For in air calibration
the film pieces were placed on low density foam blocks as shown in figure 4.7(a). The
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primary chamber was held at isocentre using a retort stand with the reference chamber
fixed to the couch as shown in figure 4.7(b).
(a) (b)
Figure 4.7: (a) In-air calibration of XR-QA2 film. Three pieces of film were used for
each exposure. The pieces were placed along the z-axis, with one at isocentre and one
directly above and below. (b) Calibration of Farmer chamber at isocentre with R/F
detector fixed to couch away from isocentre. By calibrating the isocentre dose with
the R/F detector, dose to film during exposures was able to be determined.
For in phantom calibration, the film pieces were held in place with tape within a
PMMA rod cut along its length as shown in figure 4.8(a).
The reference chamber was held in the beam away from isocentre using a retort
stand and a plastic tool which came with the Unfors package as shown in figure 4.8(b).
The film was calibrated at the centre of the PMMA phantom.
A comparison of isocentre dose to net∆R for the free-air and in phantom calibration
methods are presented in figure 4.9 for OBI and figure 4.10 for XI.
No difference in film response was observed for the OBI system between the two
calibration methods. However for the XI system, the film response was greater for
calibration in the phantom compared with free-air. The additional titanium filter in
the XI system removes low energy photons from the incident beam spectrum, however
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(a) (b)
Figure 4.8: (a) In phantom calibration of XR-QA2 film. Three pieces of film were
taped in place within a PMMA plug that was sliced along its length. The orientation
of the film pieces relative to isocentre was the same as for the in-air method. (b)
Calibration of Farmer chamber at isocentre with R/F detector held in the beam away
from isocentre.
Figure 4.9: Comparison of the calibration data for in-air and in-phantom methods
for the OBI system. No difference in film response was observed between the two
methods.
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Figure 4.10: Comparison of the calibration data for in-air and in-phantom methods
for the XI system. The response of the film was greater when calibrating in phantom
compared with calibration in air.
in the centre of the PMMA phantom lower energy scattered photons provide a signifi-
cant contribution to the measured dose [117]. The response of XR-QA2 film has been
previously shown to be around 10% higher at low energies [25] and hence, for the XI
system the response changes in air compared with in phantom. Following this result,
and the invariance of the OBI system between calibration methods, the in-phantom
calibration method was chosen.
The fitted calibration curves from the in-phantom calibration data are shown in
figure 4.11 for the OBI system and 4.12 for the XI system.
4.3.2.2 Profile Measurements
The film was cut into 30 cm by 3 cm strips for the profile measurements. The film
was scanned prior to, and post exposure following the same procedure as described in
section 4.3.2.1. Small arrows were marked in the film corners and numbered to ensure
the film position on the scanner bed was consistent as shown in figure 4.13. For each
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Figure 4.11: Calibration curve for the OBI imaging system. Error bars represent the
standard deviation in the net reflectance σnet∆R
Figure 4.12: Calibration curve for the XI imaging system. Error bars represent the
standard deviation in the net reflectance σnet∆R
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exposure the film strip was placed into the centre of the TG111 phantom using the
custom halved plug. Two strips were exposed on both the OBI and XI systems in
pelvis mode. Two CBCT scans were acquired for each strip to deliver a higher dose
to the film and remove variations due to the start/stop position of the X-Ray tube.
After film response was converted to dose from the calibration curve, the value was
halved to obtain dose from a single CBCT scan.
Figure 4.13: Film strips for beam profile measurements. The strips were cut to 3 cm
by 30 cm and placed in the centre of the TG111 phantom in a custom plug to reduce
air gaps.
The pre- and post-exposed film scans were imported into ImageJ. Line profiles
were taken for each strip and averaged for the two OBI and two XI strips. The net
reflectance was calculated from the pre and post scan data and then imported to
MATLAB and converted to dose from the OBI and XI calibration curves. The dose
profiles are shown in figure 4.14 for the OBI system and figure 4.15 for XI. The chamber
profile measurements described in section 4.3.1 are also overlayed for comparison.
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Figure 4.14: Dose profile (in cGy) along the z-axis for the OBI Pelvis scan in the
centre of the TG111 phantom measured using the Farmer chamber and 3cm by 30cm
film strip.
Figure 4.15: Dose profile (in cGy) along the z-axis for the XI Pelvis scan in the centre
of the TG111 phantom measured using the Farmer chamber and 3cm by 30cm film
strip.
The film measured a higher dose for both the OBI and XI systems, particularly in
the central region where the dose was highest. The variation for OBI at the centre
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position was 1.827 cGy for film compared with 1.525 cGy (17%) for the ionisation
chamber. The variation was less for XI with the film measuring 2.089 cGy compared
to 1.844 cGy (12%) with the ionisation chamber.
It was hypothesised the high sensitivity of XR-QA2 film to beam energy could be
causing the variation between the chamber and film. Tomic et. al. [24] showed for
beam qualities ranging from 4.03-8.25 mm Al, commonly used for CT scanning, air
KERMA varied by 14% for a dose of 8 cGy. Lillo et. al. [26] reported an increased
XR-QA2 film by as much as 170% in the energy range of 18-39 keV, while in the energy
range 38-46 keV the film response decreased. It’s worth noting that no other literature
observed variations in response above 81%. Given the scatter dose contribution to the
film likely contains energies such as these, particularly in the centre of the PMMA
phantom, high variability of film response for CBCT scans is possible. Lillo also
reports significant variation in XR-QA2 film response between studies published in
the literature for similar beam HVL values as shown in figure 4.16.
Figure 4.16: XR-QA2 dose response curves from Giaddui [25, 4], Tomic [24] and Lillo
[26]. Each curve was obtained from a polychromatic source with 120kVp. Source [26]
Variations up to 55% in film response were observed between studies by Giaddui
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[25] and Lillo [26] for similiar beam HVLs. Lillo suggests such large variations between
batches could be attributed to differences in chemical composition of sensitive and
adhesive layers regarding the lithium concentration. Further to this, Giaddui observed
two different film response curves from the same film batch of film [25, 4].
A change in response of the film due to the effects of the beam rotating compared
with a non rotating beam for calibration was also considered. When the beam is
rotated the angle of incidence of the beam on the film changes and also which side
of the film receives the primary beam (yellow face of film facing the beam to white
backing layer of film facing the beam). The angular dependance of XR-QA2 film
and effect of film facing up or down on its response has been previously investigated.
Giaddui et. al. [25] reported a variation of less than 5% for angles of 0-150 degrees
excluding 90 degrees. They also reported an identical response between film facing
up and film facing down. Rampado et. al. [119] reported similar findings for XR-
QA film with response varying by less that 1% for angles excluding 90 degrees. At
90 degrees, when the beam axis is parallel to the film surface, Giaddui reported a
decrease in response of 76% at 5.4 cGy and 81% at 2.87 cGy. Rampado reported a
49% decrease in response at 90 degrees. The change in response at 90 degrees was
attributed to several factors including attenuation of the beam when traversing the
film and a smaller fraction of the beam hitting the film surface. Following from these
results the effect of beam rotation would cause a decrease in film response, rather than
an increase which is observed.
Following maintenence of the X-Ray tube it was noted that the output of the
X-Ray tube on the OBI system measured by the Farmer chamber had increased by
8% compared with previous measurements taken 12 months earlier. An increase in
dose should not affect the response of the film, however any change in the energy
spectrum, particularly for low energies, could have a significant impact on film response
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[26, 25, 4, 118, 24].
To investigate any change in film response of the film strips due to variation in
tube output, the film profile measurements were re-taken following the methodology
previously described in 4.3.2.2. Though no change in tube output was observed for
the XI system, strip measurements were also repeated to observe whether there was
consistency in film results. The re-measured strips in the centre of the TG111 phantom
are shown in figures 4.17 and 4.18 for OBI and XI systems respectively.
Figure 4.17: Re-measured film strip in the centre of the TG111 phantom on the OBI
system.
A 9% and 20% decrease in film response was observed for the OBI and XI systems
respectively. Good agreement was achieved between the re-measured Farmer chamber
values the and XR-QA2 film across the CBCT profile for the OBI system. The film dose
was slightly higher than the chamber in the centre of the scan due to film uncertainty
and volume averaging in the chamber, however the difference was less than 4%. For
the XI system, the film under responded compared with the Farmer chamber. In the
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Figure 4.18: Re-measured film strip in the centre of the TG111 phantom on the XI
system.
centre of the profile the variation was 8%.
A further observation was the variation in film response for the strips as the X-
Ray tube heated up. Three successive film strips labelled S1-S3 were measured in the
centre of the TG111 phantom and are shown in figure 4.19. No CBCT scans had been
acquired before the strip measurements.
The dose in the centre of the film profiles decreased by 10% from S1-S3. Following
this, three additional film strips labeled S4-S6 were measured and are shown in figure
4.20.
After the tube had warmed up, it was observed that the response of the film
remained more steady. However, the average variation between the film profiles with
the tube warmed up to the Farmer chamber in the centre of the dose profile increased
to 13%.
The 9% and 20% variations in film response for the OBI and XI system are con-
sistent with the literature regarding the high sensitivity of XR-QA2 film attributed to
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Figure 4.19: Three strips measured in succession on the XI system to evaluate tube
warm up on film response. The strips were measured in order S1-S3 with no CBCT
scans acquired prior to the measurements. Also shown is the Farmer chamber dose
profile.
any minor change in energy spectrum and possible variations in chemical composition
of the film even within the same batch [26]. Variations in the output of the film,
scanner lamp, as well as the observed variations in film response due to tube warm-up
may have also contributed to change in film response.
4.4 Calculating the CTDI using Film Strips
The CTDI was calculated using the film strip profiles for OBI and XI pelvis modes
using the method described by Hu et. al. [8]. The sensitive length of the film was 30
cm and along with full scatter from the TG111 phantom overcomes the shortcomings
of the CTDI100 allowing for an accurate determination of CTDI for CBCT. In order to
make comparisons of film calculated CTDIwfilm with the other methodologies, the film
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Figure 4.20: Three additional strips S4-S6 measured in succession on the XI system
after the X-Ray tube had warmed up. Also shown is the Farmer chamber dose profile.
profiles were first normalised relative to the central ionisation chamber measurements
as shown in figures 4.21 and 4.22. Since the methodologies were evaluated prior to
the change in output of the X-Ray tube on the OBI system, the film profiles were
normalised to the initial chamber profile measurements. Error bars indicate the ob-
served variations of ±4.5% and ±10% in film response between the two sets of strip
measurements for OBI and XI systems respectively.
Film strips were exposed in the central position and each of the peripheral locations
within the phantom for OBI and XI systems as described in section 4.3.2.2. The DLI
was computed from the summation of each pixel value PVi along the strip profile
multiplied by the distance between successive pixel values d, obtained from the length
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Figure 4.21: Film profile in the centre of the TG111 phantom for a OBI Pelvis mode
CBCT scan and the profile normalised to the central ionisation chamber measurements
taken prior to the change in X-Ray tube output. Error bars represent the observed
±4.5% variation in the OBI film profiles.
Figure 4.22: Film profile in the centre of the TG111 phantom for a XI Pelvis mode
CBCT scan and the profile normalised to the central ionisation chamber measurement.
Error bars represent the observed ±10% variation in the XI film profiles.




PVi ∗ d (4.10)
CTDIwfilm was then calculated using the DLIs from the central and peripheral
positions within the phantom and z-axis collimation using equations 3.2 and 3.5.
Standard deviation in the CTDIwfilm was calculated using the total uncertainty
in the calibration curve. This was determined from the standard deviation in the







The σCTDIwfilm was then determined by caluclating the DLI of standard deviation









A comparison of CTDIwfilm to the TG111 method is shown in table 4.4.
Imaging System TG111w (mGy) CTDI
w
film (mGy)
OBI 21.20 ± 0.01 20.47 ± 0.71
XI 22.42 ± 0.01 21.28 ± 0.44
Table 4.4: Comparison of TG111w with CTDI
w
film in mGy for the OBI and XI imaging
systems
The TG111 measured 0.73 mGy higher for the OBI system and 1.14 mGy higher
for the XI system compared with CTDIwfilm. The small difference between methods
is consistent with the under-response of the film observed previously and well within
the uncertainty of sensitivity for XR-QA2 film [24, 25, 26, 119]. A small fraction of
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the dose profile may have also fallen beyond the 30cm length of the film strip, which
would cause a small under estimation of the DLI.
The CTDIwfilm measurements were within 5% of the TG111 which correlates well
with the 3|5 agreement between the film and TG111 methods oberved by Hu et. al.
[8]. The result validate the TG111 method as an accurate representation of CTDI
with sufficient detector and phantom length. The result also validates the CBDI as




This thesis presents work quantifying the dose output for two commercial kV CBCT
imaging systems for use during image guided radiotherapy. The major objectives of
this thesis, as outlined by the aims in chapter 1 were:
• Evaluate and compare the current CTDI protocol with three alternate method-
ologies, the Cone-Beam Dose Index method adapted for wide beam scanning
[13], the International Atomic Energy Agency Report No. 5 suggested approach
for wide beam dosimetry [11] and the American Association of Physicists in
Medicine Task Group 111 methodology[12] [Section 5.1].
• Evaluate and compare methodologies for varying beam width, specifically for
clinical settings and compare between the listed protocols [Section 5.2], and
• Compare dose between two Varian imaging systems: the OBIr on the C-Series
platform and XIr on Truebeam [Section 5.3].
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5.1 Comparison of TG111, CBDI and IAEA method-
ologies with the current CTDI method
The dose from two commercial kV CBCT systems, the Varian Cliniacr iX On-Board
Imager (OBI) and the Varian TruebeamTM X-Ray Imager (XI) were evaluated using
four methodologies, the American Association of Physicists in Medicine Task Group
111 approach (TG111)[12], the International Atomic Energy Agency Report 5 rec-
ommendation (IAEA)[11], the Cone-Beam Dose Index (CBDI)[13] and the current
paradigm, the Computed Tomography Dose Index (CTDI)[31], and the results com-
pared. The methodologies were evaluated on clinically relevant imaging modes for
each system. For the OBI system: Pelvis, Thorax, Low Dose, High Dose and Stan-
dard Dose Head modes were evaluated. On the XI system: Pelvis, Pelvis Obese,
Thorax and Head modes were evaluated.
The TG111 approach measured the highest overall dose across both OBI and XI due
to the increased length of the custom phantom. The added length created a maximum
scatter contribution to the central measurement and therefore the highest dose. The
CBDI measured the second highest dose overall using the existing CTDI phantom and
pencil chamber from the CTDI method. The CBDI method was an up-scaling of the
CTDI by dividing the integral dose by the sensitive chamber length of 100 mm rather
than the collimation width. The dose from this method gave similar results to the
TG111. The IAEA approach measured the third highest dose and was significantly
lower than CBDI and TG111 due to the lack of scatter and no scaling factor. However
the IAEA approach does capture the full beam width for calculating integral dose,
which translated into a constant dose for the wide beam widths of CBCT. The CTDI
gave the lowest dose of all the methodologies.
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5.2 Comparison of dose with varying beam width
for TG111, CBDI, IAEA and CTDI, including
Integral Dose
Both the TG111 and CBDI methods asymptotically approached a maximum value for
increasing beam width, with the TG111 maximum being slightly higher than CBDI.
The dose at 40 cm width was 22.45 mGy for TG111 and 20.19 mGy for CBDI on
the OBI Pelvis mode. The maximum value occurred when full scatter was achieved
on the ionisation chamber. The IAEA method did not increase beyond 15 cm beam
width due to the shorter phantom not having sufficient scatter as the beam width was
increased. However the IAEA does capture the full dose profile and remains relatively
constant from 15 cm out to to 40 cm. The CTDI reached its maximum at 10 cm
beam width then decreased as the beam was increased to 40 cm. The CTDI phantom
lacks sufficient length to achieve full scatter and the 100 mm sensitive chamber length
is not sufficient to capture the full beam profile. This was confirmed by dose profile
measurements in the centre of the TG111 phantom for the Pelvis OBI and XI scans.
The beam profiles extended beyond the collimated beam width, only dropping to 62%
and 58% of the maximum values at ± 10 cm respectively. The underestimation of
CTDI became worse as the beam continued to increase. The underestimation was
compounded as the divisor in the CTDI, the collimation width, was increased.
The integral dose increased linearly with beam width with higher mAs scans trans-
lating to steeper increases. The increase with beam width was greater than for the
TG111, CBDI, IAEA and CTDI where dose in the central axis of the phantom is used
in the calculations. The result highlights the necessity to limit beam width in CBCT
imaging to what is required particularly for scans with a high mAs.
Dose profiles taken with diagnostic GafchromicTM XR-QA2 film and used to cal-
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culate a weighted CTDIwfilm in the TG111 phantom for OBI and XI Pelvis modes.
The full scatter and 30 cm length of the film strips overcame the shortcomings of the
CTDI100. The CTDI
w
film and TG111 values were in good agreement with CTDI
w
film
measuring 20.47 ± 0.71 mGy compared with 21.20 ± 0.01 mGy using the TG111
method on the OBI system and 21.28 ± 0.44 mGy and 22.42 ± 0.01 mGy for the XI
system for the respective methods. This validated the TG111 as an accurate repre-
sentation of the CTDI when sufficient detector and phantom lengths are used. The
result also confirms the CBDI as a good approximation to the accurate CTDI value
using existing dosimetry equipment.
5.3 Comparing the dose of the OBI and XI kV
CBCT imaging systems
The overall dose was higher for the OBI system. For Pelvis modes the OBI measured
21.199 ± 0.014 mGy compared with 18.246 ± 0.001 mGy for XI using the TG111
method. For Thorax the OBI measured 6.963 ± 0.001 mGy compared with 5.540 ±
0.000 mGy for XI. Comparing equivalent Head protocols on the two systems, Standard
Head OBI with Head XI, the OBI was higher measuring 4.605 ± 0.003 mGy compared
with 3.527 ± 0.002 mGy for XI using the CBDI method. The higher OBI values are
attributed to its higher photon fluence compared with the XI due to the additional
low energy photons in its spectrum.
5.4 Summary and Future Work
Three alternative methods for quantifying kV CBCT dose during image guidance
procedures were evaluated and compared to the existing CTDI100 method on two
commercial imaging systems, the Varian OBIr on the C-Series platform and XIr on
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Truebeam. The CTDI100 was shown to underestimate the dose due to an insufficient
detector length to capture the full dose profile and phantom length to achieve scatter
equilibrium. The three alternate methods provided a better approximation with the
TG111 method giving the best representation of CTDI when the full profile is collected
and full scatter is achieved, which was calculated using Gafchromicr QR-QA2 film
strips and a custom built TG111 phantom.
The OBI imaging system delivered similar doses for pelvis mode scanning and
higher doses in thorax mode scanning compared with the XI system across all protocols
due to a reduction in low energy photons in the XI beam. The CBCT beam was also
shown to extend beyond the collimation width in the centre of the PMMA phantom
due to beam divergence.
The TG111 method should be applied to give the best estimate of CBCT dose due
to the full scatter phantom. However, the CBDI method may be more readily applied
clinically due to the use of existing CTDI equipment and measurement methods and
will give a close approximation to TG111. A possible approach is to measure TG111
for clinical CBCT modes and scale this to CTDI measurements, which can be more
easily taken periodically to evaluate scanner output.
The scope for future work includes:
• Investigating out of field and skin doses from CBCT scanning,
• Determining patient specific dose estimates from CBCT scans, and deriving a
relationship between patient specific dose and protocol measurements,
• Using risk models to assess the increased risk of radiation-induced secondary
malignancies following CBCT imaging regimes during radiotherapy,
• Incorporating imaging dose calculations into treatment planning systems,
• Investigate optimal image quality requirements to minimise CBCT imaging dose
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• Development of a universal CBCT dosimetry protocol, similar to the TG111
for CT scanning, which would be independent of scanner settings, which could
facilitate comparisons between imaging systems between clinics.
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